

Published, ongoing & planned projects				
Title	Status	No.	Year	Download/Link
<b>HTA Project Reports</b>				
Therapeutic conversation: The effectiveness of intensified physician-patient communication	published	1	2006	<a href="http://eprints.hta.lbg.ac.at/22/">http://eprints.hta.lbg.ac.at/22/</a>
Horizon Scanning System (HSS) - An Overview	published	2	2006	<a href="http://eprints.hta.lbg.ac.at/586/">http://eprints.hta.lbg.ac.at/586/</a>
External manual. Part 1	published	3	2007	<a href="http://eprints.hta.lbg.ac.at/714/">http://eprints.hta.lbg.ac.at/714/</a>
Neonatal care of low-risk newborns. An approach to evidence-based health care planning in Styria	published	4	2007	<a href="http://eprints.hta.lbg.ac.at/693/">http://eprints.hta.lbg.ac.at/693/</a>
Role and positioning of university outpatient departments	published	5	2007	<a href="http://eprints.hta.lbg.ac.at/38/">http://eprints.hta.lbg.ac.at/38/</a>
Internal manual. Part 2 (2nd Ed.)	published	6	2009	<a href="http://eprints.hta.lbg.ac.at/713/">http://eprints.hta.lbg.ac.at/713/</a>
Mammography screening. Evidence-based evaluation of mammography-based breast cancer screening programmes	published	7	2007	<a href="http://eprints.hta.lbg.ac.at/715/">http://eprints.hta.lbg.ac.at/715/</a>
Testing for HER2 positive breast cancer. Challenge for improvement of current conditions and practice	published	8	2007	<a href="http://eprints.hta.lbg.ac.at/716/">http://eprints.hta.lbg.ac.at/716/</a>
Economic evaluation of HPV vaccination in Austria	published	9	2007	<a href="http://eprints.hta.lbg.ac.at/760/">http://eprints.hta.lbg.ac.at/760/</a>
Economic aspects of clinically effective and efficient models of health services in alcohol addiction treatment - Part I: International models and approaches of outcome measurement, Part 2: Selected models of integrated care and their evaluation, Part 3: ongoing	published	10	2009	<a href="http://eprints.hta.lbg.ac.at/823/">http://eprints.hta.lbg.ac.at/823/</a>
Clinical and health economic registries in the field of cardiovascular, spinal and neurologic diseases. Methods and good practice strategies	published	11	2008	<a href="http://eprints.hta.lbg.ac.at/788/">http://eprints.hta.lbg.ac.at/788/</a>
Back pain. Diagnosis and treatment according to evidence-based guidelines - options and limitations.	published	12	2008	<a href="http://eprints.hta.lbg.ac.at/794/">http://eprints.hta.lbg.ac.at/794/</a>
Clinical application of Tissue Engineering. An overview of International and Austrian Areas of Research with a critical analysis of selected applications	published	13	2008	<a href="http://eprints.hta.lbg.ac.at/807/">http://eprints.hta.lbg.ac.at/807/</a>
Horizon Scanning in Oncology - Concept Development for the Preparation of a Horizon Scanning System in Austria	published	14	2008	<a href="http://eprints.hta.lbg.ac.at/798/">http://eprints.hta.lbg.ac.at/798/</a>
Outpatient Cardiac Rehabilitation. Part 1: Evaluation and Indicators. Part 2: Comparative analysis of various rehabilitation models and Phase III	published	15	2008	<a href="http://eprints.hta.lbg.ac.at/800/">http://eprints.hta.lbg.ac.at/800/</a>
Clinical Pathways: Systematic Review of outcome parameters and effectiveness	published	16	2008	<a href="http://eprints.hta.lbg.ac.at/801/">http://eprints.hta.lbg.ac.at/801/</a>
Clavicular Fractures - A systematic review about efficacy and safety of different treatment options	published	17	2008	<a href="http://eprints.hta.lbg.ac.at/816/">http://eprints.hta.lbg.ac.at/816/</a>
Statins for the Secondary Prevention of Cardiovascular Diseases: An Analysis of Expected Population Health Gains and Cost-Utility in Austria (Part 2 of the project 'Statins: A comparison between predicted and actual effects on population health in Austria)	published	18	2008	<a href="http://eprints.hta.lbg.ac.at/803/">http://eprints.hta.lbg.ac.at/803/</a>
Have Statins Met Our Expectations? A Comparison of Expected Health Gains from Statins with Epidemiological Trends in Austria (Part 3 of the Project 'Statins: A Comparison Between Predicted and Actual Effects on Population Health in Austria).	published	19	2008	<a href="http://eprints.hta.lbg.ac.at/804/">http://eprints.hta.lbg.ac.at/804/</a>
Folic acid fortification of flour in Austria - Risks and benefits	published	20	2009	<a href="http://eprints.hta.lbg.ac.at/847/">http://eprints.hta.lbg.ac.at/847/</a>
Evidence supported health service planning	published	21	2009	<a href="http://eprints.hta.lbg.ac.at/843/">http://eprints.hta.lbg.ac.at/843/</a>
Reimbursement processes – An analysis of international practice models for maintaining the health benefit baskets of solidly financed health care systems	published	22	2008	<a href="http://eprints.hta.lbg.ac.at/817/">http://eprints.hta.lbg.ac.at/817/</a>
Classification of disease severity for neuro- and trauma rehabilitation - Part 1: instruments for stroke and traumatic brain injury	published	23a	2009	<a href="http://eprints.hta.lbg.ac.at/866/">http://eprints.hta.lbg.ac.at/866/</a>
Classification of disease severity for neuro- and trauma rehabilitation - Part 2: International experiences with quality / performance assessments and reimbursement	published	23b	2009	<a href="http://eprints.hta.lbg.ac.at/867/">http://eprints.hta.lbg.ac.at/867/</a>
Classification of disease severity for neuro- and trauma rehabilitation - Part 3: Status quo s in Austria	published	23c	2010	<a href="http://eprints.hta.lbg.ac.at/879/">http://eprints.hta.lbg.ac.at/879/</a>
Coverage with Evidence Development - Experiences from selected countries	published	24	2009	<a href="http://eprints.hta.lbg.ac.at/818/">http://eprints.hta.lbg.ac.at/818/</a>
Kyphoplasty and vertebroplasty for the treatment of osteoporotic vertebral compression fractures- observational study.	published	25	2010	<a href="http://eprints.hta.lbg.ac.at/900/">http://eprints.hta.lbg.ac.at/900/</a>
Developing a decision aid on HPV-vaccination for young girls and women/ mothers	published	26	2009	<a href="http://www.hpv-entscheidungshilfe.de/">http://www.hpv-entscheidungshilfe.de/</a>
Evaluations of child and adolescent psychiatry. (Part 1a) - Theory and practice about measurement dimensions, indicators and instruments.	published	27	2009	<a href="http://eprints.hta.lbg.ac.at/846/">http://eprints.hta.lbg.ac.at/846/</a>
Child and adolescent psychiatry. (Part 1b) - A systematic review of health economic evaluations	published	28	2009	<a href="http://eprints.hta.lbg.ac.at/862/">http://eprints.hta.lbg.ac.at/862/</a>
Child and adolescent psychiatry. (Part 2) - Evaluation study at the University Department of Child and Adolescent Psychiatry (Christian-Doppler-Klinik) in Salzburg	ongoing	40		
Telemedicine in Stroke Management. Systematic Review.	published	29	2009	<a href="http://eprints.hta.lbg.ac.at/844/">http://eprints.hta.lbg.ac.at/844/</a>
Tocolysis in preterm labour - A systematic review of evidence-based guidelines, effectiveness and health economic evaluations	published	30	2009	<a href="http://eprints.hta.lbg.ac.at/825/">http://eprints.hta.lbg.ac.at/825/</a>
Outpatient cardiac rehabilitation. Part 3a: Retrospective cohort study (with/without phase III rehabilitation - Explorative analysis and developing of an evaluation plan	published	31a	2010	<a href="http://eprints.hta.lbg.ac.at/875/">http://eprints.hta.lbg.ac.at/875/</a>
Outpatient cardiac rehabilitation. Part 3b: Retrospective cohort study (with/without phase III rehabilitation - Application of the evaluation plan	published	31b	2010	<a href="http://eprints.hta.lbg.ac.at/876/">http://eprints.hta.lbg.ac.at/876/</a>
Horizon scanning in oncology - Part 2: From pilot to routine	ongoing	32		siehe HSS Publikationen ganz unten
Artificial food colours and Hyperactivity	published	34	2009	<a href="http://eprints.hta.lbg.ac.at/848/">http://eprints.hta.lbg.ac.at/848/</a>
Status quo Mammography screening. Evaluation results from organised programs	published	35	2009	<a href="http://eprints.hta.lbg.ac.at/863/">http://eprints.hta.lbg.ac.at/863/</a>
Evaluation of diagnostic technologies – background, challenges, methods	published	36	2010	<a href="http://eprints.hta.lbg.ac.at/898/">http://eprints.hta.lbg.ac.at/898/</a>
Impact from HTA-research for the Austrian health care system. Part 1: Overview - Update	published	37a	2010	<a href="http://eprints.hta.lbg.ac.at/877/">http://eprints.hta.lbg.ac.at/877/</a>
Impact from HTA-research for the Austrian health care system. Part 2: Results of the empirical survey	published	37b	2011	<a href="http://eprints.hta.lbg.ac.at/907/">http://eprints.hta.lbg.ac.at/907/</a>
Acquisition Processes of Certain Product Groups in Hospitals - Orthopaedic and Cardiac Implants	published	38	2009	<a href="http://eprints.hta.lbg.ac.at/864/">http://eprints.hta.lbg.ac.at/864/</a>
Haemocompletan® P and Fibrogammin® P in acquired hypofibrinogenemia	published	39	2009	<a href="http://eprints.hta.lbg.ac.at/870/">http://eprints.hta.lbg.ac.at/870/</a>
Screening for Colorectal Cancer. Part 1: Screening-Tests and Project Design	published	41a	2010	<a href="http://eprints.hta.lbg.ac.at/873/">http://eprints.hta.lbg.ac.at/873/</a>

Last update: 6.12.2022

Title	Status	No.	Year	Download/Link
Screening for Colorectal Cancer. Part 2: Health economic evaluations and developments of costs	published	41b	2010	<a href="http://eprints.hta.lbg.ac.at/874/">http://eprints.hta.lbg.ac.at/874/</a>
IFEDH - Innovative Framework for Evidence Based Decision Making in Health Care - Principles of standardised work in HTA (WP1.2)	published	44a	2011	<a href="http://eprints.hta.lbg.ac.at/932/">http://eprints.hta.lbg.ac.at/932/</a>
IFEDH - Innovative Framework for Evidence Based Decision Making in Health Care - Glossary of terms (WP2.1)	finished	44b	2011	not published
Reorientation of the Austrian parent-child preventive care programme. Part 1: Epidemiology - incidence of risk factors and diseases in pregnancy and early childhood	published	45a	2011	<a href="http://eprints.hta.lbg.ac.at/912/">http://eprints.hta.lbg.ac.at/912/</a>
Reorientation of the Austrian parent-child preventive care programme. Part 2: International Policies, approaches and screening strategies to "normal" and "risk experiences" during pregnancy and early childhood to school entry	published	45b	2011	<a href="http://eprints.hta.lbg.ac.at/913/">http://eprints.hta.lbg.ac.at/913/</a>
Reorientation of the Austrian parent-child preventive care programme. Part 3: Status quo of the financing and cost structures of parent-child services in Austria	published	45c	2011	<a href="http://eprints.hta.lbg.ac.at/914/">http://eprints.hta.lbg.ac.at/914/</a>
Reorientation of the Austrian parent-child preventive care programme. Part 4: Synthesis of Parts 1-3, Recommendations	published	45d	2011	<a href="http://eprints.hta.lbg.ac.at/915/">http://eprints.hta.lbg.ac.at/915/</a>
Gamma Knife versus adapted linear accelerators: A comparison of two radiosurgical applications	published	47	2010	<a href="http://eprints.hta.lbg.ac.at/901/">http://eprints.hta.lbg.ac.at/901/</a>
Strengthening the evidence base for a learning health system - Inspirations from good practice for capacity building in health services research and public health research	published	48	2011	<a href="http://eprints.hta.lbg.ac.at/908/">http://eprints.hta.lbg.ac.at/908/</a>
Quality of care in oncology and its measurement	published	49a	2011	<a href="http://eprints.hta.lbg.ac.at/934/">http://eprints.hta.lbg.ac.at/934/</a>
Generic indicators for process quality in oncological care. A compendium	published	49b	2012	<a href="http://eprints.hta.lbg.ac.at/946/">http://eprints.hta.lbg.ac.at/946/</a>
Reorientation of the Austrian parent-child preventive care programme. Part 5: Preterm birth	published	50	2012	<a href="http://eprints.hta.lbg.ac.at/939/">http://eprints.hta.lbg.ac.at/939/</a>
Systematic review of the efficacy and safety of treatments for varicose veins of the lower extremity	published	51	2011	<a href="http://eprints.hta.lbg.ac.at/930/">http://eprints.hta.lbg.ac.at/930/</a>
Appraisal of the quality and accuracy of written consumer health information for patients with chronic myeloid leukaemia on treatment-regimens with dasatinib, imatinib or nilotinib	published	52	2012	<a href="http://eprints.hta.lbg.ac.at/953/">http://eprints.hta.lbg.ac.at/953/</a>
Reorientation of the Austrian parent-child preventive care programme. Part 6: Health visiting services in the international context and implementation options for Austria	published	53	2012	<a href="http://eprints.hta.lbg.ac.at/947/">http://eprints.hta.lbg.ac.at/947/</a>
Reorientation of the Austrian parent-child preventive care programme. Part 7: Options for an electronic implementation	published	54	2012	<a href="http://eprints.hta.lbg.ac.at/948/">http://eprints.hta.lbg.ac.at/948/</a>
Reorientation of the Austrian parent-child preventive care programme. Part 8: Budget Impact Analysis	published	55	2012	<a href="http://eprints.hta.lbg.ac.at/949/">http://eprints.hta.lbg.ac.at/949/</a>
Occupational therapy in Austria	published	56	2012	<a href="http://eprints.hta.lbg.ac.at/972/">http://eprints.hta.lbg.ac.at/972/</a>
Disinvestment. Overview of disinvestment experiences and challenges in selected countries.	published	57	2011	<a href="http://eprints.hta.lbg.ac.at/926/">http://eprints.hta.lbg.ac.at/926/</a>
Standards on how to parameterise models via published literature - Input of the LBI HTA for IFEDH workpackage 4	published	58	2012	<a href="http://eprints.hta.lbg.ac.at/990/">http://eprints.hta.lbg.ac.at/990/</a>
Occupational therapy Part 3 – Occupational therapy for patients after stroke	published	59	2012	<a href="http://eprints.hta.lbg.ac.at/973/">http://eprints.hta.lbg.ac.at/973/</a>
Occupational Therapy Part 4 for Dementia and Part V for Depression	published	60	2012	<a href="http://eprints.hta.lbg.ac.at/974/">http://eprints.hta.lbg.ac.at/974/</a>
Horizon Scanning in Oncology - Impact Evaluation	published	61	2012	<a href="http://eprints.hta.lbg.ac.at/969/">http://eprints.hta.lbg.ac.at/969/</a>
Reorientation of the Austrian parent-child preventive care programme - Part 9: Evidence-based screening guidelines for pregnant women and children (0 – 6 yrs.)	published	62	2013	<a href="http://eprints.hta.lbg.ac.at/996/">http://eprints.hta.lbg.ac.at/996/</a>
(III) Health and access to health care in homeless people: A literature review	published	63	2012	<a href="http://eprints.hta.lbg.ac.at/980/">http://eprints.hta.lbg.ac.at/980/</a>
Day Surgery: A Systematic Overview	published	64	2012	<a href="http://eprints.hta.lbg.ac.at/987/">http://eprints.hta.lbg.ac.at/987/</a>
Screening for Colorectal Cancer. Part 1: Screening Tests and Program Design (3. updated edition)	published	41a	2012	<a href="http://eprints.hta.lbg.ac.at/981/">http://eprints.hta.lbg.ac.at/981/</a>
Screening for Colorectal Cancer. Part 2: Health economic evaluations and cost dynamics (2. updated edition)	published	41b	2012	<a href="http://eprints.hta.lbg.ac.at/982/">http://eprints.hta.lbg.ac.at/982/</a>
Screening for Colorectal Cancer. Part 3: update von Teil 1 (41 a) und Teil 2 (41 b), Quality of screening colonoscopy	published	41c	2013	<a href="http://eprints.hta.lbg.ac.at/983/">http://eprints.hta.lbg.ac.at/983/</a>
Marketing Authorisations under Exceptional Circumstances for Oncology Drugs	published	65	2013	<a href="http://eprints.hta.lbg.ac.at/992/">http://eprints.hta.lbg.ac.at/992/</a>
Outpatient cardiac rehabilitation; Part 6: Scientific monitoring of the "Multi-centre, prospective cohort study with two control groups (with/without phase III)"	ongoing	66		
„Mental Health“ rehabilitation for children and adolescents – A literature overview on indications, outcomes and evaluation instruments	published	67	2013	<a href="http://eprints.hta.lbg.ac.at/1012/">http://eprints.hta.lbg.ac.at/1012/</a>
Identifying ineffective interventions and health technologies: models and their implementation	published	68	2013	<a href="http://eprints.hta.lbg.ac.at/1014/">http://eprints.hta.lbg.ac.at/1014/</a>
Treatment by clinical psychologists. Part 1: Overview of training requirements and systematic stakeholder analysis on delineation of areas of responsibility and treatment methods.	published	69a	2013	<a href="http://eprints.hta.lbg.ac.at/1018/">http://eprints.hta.lbg.ac.at/1018/</a>
Treatment by clinical psychologists. Part 2: Literature overview on methods of treatment and areas of application.	published	69b	2013	<a href="http://eprints.hta.lbg.ac.at/1019/">http://eprints.hta.lbg.ac.at/1019/</a>
Occupational therapy in children. Part 1 – Literature review on indications, utilisation and recommendations	published	70	2013	<a href="http://eprints.hta.lbg.ac.at/1016/">http://eprints.hta.lbg.ac.at/1016/</a>
Cost- and Budget-Impact-Analysis of an Increase in Day Surgery for Selected Indications	published	71	2014	<a href="http://eprints.hta.lbg.ac.at/1035/">http://eprints.hta.lbg.ac.at/1035/</a>
p16/KI-67 Dual Stain in cytological screening of cervical cancer: A systematic literature review of clinical studies based on a review of methodological approaches for assessing biomarkers	published	72	2013	<a href="http://eprints.hta.lbg.ac.at/1009/">http://eprints.hta.lbg.ac.at/1009/</a>
Evidence requirements for the authorisation and reimbursement of high risk medical devices in USA, Australi and Canada	published	73	2013	<a href="http://eprints.hta.lbg.ac.at/1017/">http://eprints.hta.lbg.ac.at/1017/</a>
Proton- and Carbon Ion therapy	published	74	2013	<a href="http://eprints.hta.lbg.ac.at/1021/">http://eprints.hta.lbg.ac.at/1021/</a>
Sustainability of inpatient psychiatric rehabilitation for adults: systematic review	published	75	2014	<a href="http://eprints.hta.lbg.ac.at/1025/">http://eprints.hta.lbg.ac.at/1025/</a>
Positron emission tomography/ Computer tomography (PET/ CT): need-assessment for planning	published	77	2015	<a href="http://eprints.hta.lbg.ac.at/1045/">http://eprints.hta.lbg.ac.at/1045/</a>
Acupuncture - areas of application, current evidence and proven indications	published	78	2014	<a href="http://eprints.hta.lbg.ac.at/1042/">http://eprints.hta.lbg.ac.at/1042/</a>
Vasoprotectives: Efficacy and safety of capillary stabilising agents for venous insufficiency or haemorrhoids	published	79	2014	<a href="http://eprints.hta.lbg.ac.at/1047/">http://eprints.hta.lbg.ac.at/1047/</a>
Criteria and recommendations for an adequate use of Magnetic Resonance Imaging (MRI)	published	80	2014	<a href="http://eprints.hta.lbg.ac.at/1043/">http://eprints.hta.lbg.ac.at/1043/</a>
Lithuania: HTA Training	finished	81	2015	not published
Adequacy of MRI 2	finished	82		not published
Effects of (im)material incentives on health behaviour. Part I: Definitions, theories and models and Part II: Overview of reviews covering 4 health issues	published	83	2015	<a href="http://eprints.hta.lbg.ac.at/1078/">http://eprints.hta.lbg.ac.at/1078/</a>
Robotic Surgery	published	84	2015	<a href="http://eprints.hta.lbg.ac.at/1077/">http://eprints.hta.lbg.ac.at/1077/</a>
Endovascular stroke therapy	finished	85		not published
Patient- and citizen participation in HTA processes - Good Practice	published	86	2016	<a href="http://eprints.hta.lbg.ac.at/1088/">http://eprints.hta.lbg.ac.at/1088/</a>

Title	Status	No.	Year	Download/Link
Nudging -Behavioral Sciences applied to the Big Four Public Health issues	published	83/ Addendum	2015	<a href="http://eprints.hta.lbg.ac.at/1078/">http://eprints.hta.lbg.ac.at/1078/</a>
Mechanical thrombectomy in acute ischemic stroke. Patient characteristics, structural requirements and (differential) diagnosis	published	87	2016	<a href="http://eprints.hta.lbg.ac.at/1084/">http://eprints.hta.lbg.ac.at/1084/</a>
New concept for primary care (Supply mandates)	published	88	2016	<a href="http://eprints.hta.lbg.ac.at/1110/">http://eprints.hta.lbg.ac.at/1110/</a>
Outpatient cardiac rehabilitation, Part 6: Economic evaluation	published	89	2016	<a href="http://eprints.hta.lbg.ac.at/1102/">http://eprints.hta.lbg.ac.at/1102/</a>
Options to identify inappropriate use of MRI, Part 3	published	80c	2015	<a href="http://eprints.hta.lbg.ac.at/1159/">http://eprints.hta.lbg.ac.at/1159/</a>
Opportunities and strategies to drive appropriate use of MRI in Austria. Part 2	published	80b	2015	<a href="http://eprints.hta.lbg.ac.at/1090/">http://eprints.hta.lbg.ac.at/1090/</a>
Outpatient cardiac rehabilitation, Part 6: Scientific monitoring of the Multi-centre, prospective cohort study with two control groups (with/without phase III)	published	90	2016	<a href="http://eprints.hta.lbg.ac.at/1101/">http://eprints.hta.lbg.ac.at/1101/</a>
Reorientation of the Austrian parent-child preventive care programme. Part 12: Economic evaluation of selected screenings during pregnancy	published	91	2017	<a href="http://eprints.hta.lbg.ac.at/1112/">http://eprints.hta.lbg.ac.at/1112/</a>
Reorientation of the Austrian parent-child preventive care programme - Part 9: Evidence-based screening guidelines for pregnant women and children (0 – 6 yrs.)	published	62/Update 2016	2016	<a href="http://eprints.hta.lbg.ac.at/996/">http://eprints.hta.lbg.ac.at/996/</a>
Re-orientation of the Austrian parent-child preventive care programme. Part 11: Screening recommendations of the expert working group for pregnancy	published	92	2019	<a href="http://eprints.hta.lbg.ac.at/1163/">http://eprints.hta.lbg.ac.at/1163/</a>
Legally recognized psychotherapy methods in Austria – effect factors, indications, setting specific aspects	published	93	2017	<a href="http://eprints.hta.lbg.ac.at/1143/">http://eprints.hta.lbg.ac.at/1143/</a>
Telekardiologie - Map Ö and evaluation methods: Work in Progress	finished	94	2017	not published
Transcatheter Aortic Valve Implantation Part 1: A systematic review of economic evaluations	published	95a	2017	<a href="http://eprints.hta.lbg.ac.at/1139/">http://eprints.hta.lbg.ac.at/1139/</a>
Social Return on Investment* for Child and Adolescence Health: Outcomes, Methods and Economic Parameters	published	96	2017	<a href="http://eprints.hta.lbg.ac.at/1142/">http://eprints.hta.lbg.ac.at/1142/</a>
Perinatal Care at the threshold of viability. Part I Resource planning for Neonatal Care Units: clinical outcomes and resource needs				
Part II (Good) Practice Models to handle Ethical, Organizational, and Social Challenges	published	97a	2018	<a href="http://eprints.hta.lbg.ac.at/1146/">http://eprints.hta.lbg.ac.at/1146/</a>
Perinatal Care at the threshold of viability Part II: Decision-making at the threshold of viability and ethical challenges at Neonatal Intensive Care Units (NICUs)	published	97b	2018	<a href="http://eprints.hta.lbg.ac.at/1148/">http://eprints.hta.lbg.ac.at/1148/</a>
Transthoracic Echocardiography (TAVI) Part 1: Use in Austria and Guideline Recommendations for Appropriate Use	published	98		<a href="http://eprints.hta.lbg.ac.at/1158/">http://eprints.hta.lbg.ac.at/1158/</a>
Transcatheter Aortic Valve Implantation (TAVI) Part 2: Frequency, Patient Collective, and Geographic Variation Over Time in Austria	published	95b	2017	<a href="http://eprints.hta.lbg.ac.at/1141/">http://eprints.hta.lbg.ac.at/1141/</a>
PET/PET-CT Evidence for need based planning in Germany and Austria	published	77/Update 2018	2018	<a href="http://eprints.hta.lbg.ac.at/1178/">http://eprints.hta.lbg.ac.at/1178/</a>
*Dropouts in psychotherapies – Theoretical reflections and counter-strategies	published	100	2018	<a href="http://eprints.hta.lbg.ac.at/1157/">http://eprints.hta.lbg.ac.at/1157/</a>
Carbon ion beam radiotherapy (CIRT) for cancer treatment: a systematic review of effectiveness and safety for 12 oncologic indications	published	101	2018	<a href="http://eprints.hta.lbg.ac.at/1174/">http://eprints.hta.lbg.ac.at/1174/</a>
Genexpressionstest MammaPrint® zur Entscheidungs-unterstützung für/gegen adjuvante Chemotherapie bei primärem Brustkrebs	published	102	2018	<a href="http://eprints.hta.lbg.ac.at/1147/">http://eprints.hta.lbg.ac.at/1147/</a>
Screening of fetal trisomes 21, 18 and 13 by noninvasive prenatal testing	published	103	2018	<a href="http://eprints.hta.lbg.ac.at/1153/">http://eprints.hta.lbg.ac.at/1153/</a>
Inhalation sedation with laughing gas (N2O) in dentistry – organisational and professional aspects and a systematic review of efficacy and safety	published	105	2018	<a href="http://eprints.hta.lbg.ac.at/1182/">http://eprints.hta.lbg.ac.at/1182/</a>
Screening programmes for children and adolescents aged 6-14 years in selected countries and recommendations from evidence-based guidelines	published	106	2018	<a href="http://eprints.hta.lbg.ac.at/1212/">http://eprints.hta.lbg.ac.at/1212/</a>
Stereotactic radiotherapy (Cyberknife®), proton beam therapy and irreversible (electroporation Nanoknife®) for localised prostate cancer (PCa): a systematic review	published	107	2018	<a href="http://eprints.hta.lbg.ac.at/1165/">http://eprints.hta.lbg.ac.at/1165/</a>
Robot-assisted surgery: A systematic review of effectiveness and safety in thoracic and visceral surgery	published	108	2019	<a href="http://eprints.hta.lbg.ac.at/1198/">http://eprints.hta.lbg.ac.at/1198/</a>
Pricing and reimbursement in the inpatient sector in Austria: Approaches for a transparent and evidence-based process taking into account international experience	published	109	2019	<a href="http://eprints.hta.lbg.ac.at/1183/">http://eprints.hta.lbg.ac.at/1183/</a>
EditTechnology Forecast: advanced therapies in late clinical research, EMA approval or clinical application via hospital exemption	published	111		<a href="http://eprints.hta.lbg.ac.at/1197/">http://eprints.hta.lbg.ac.at/1197/</a>
Natalizumab as treatment for Multiple Sclerosis: a systematic review	published	112	2019	<a href="http://eprints.hta.lbg.ac.at/1190/">http://eprints.hta.lbg.ac.at/1190/</a>
Uptake of mental health care benefits (co-) funded by the Tyrolean health insurance (Village)	published	113a	2019	<a href="http://eprints.hta.lbg.ac.at/1180/">http://eprints.hta.lbg.ac.at/1180/</a>
Prevalence of mental disorders and uptake of mental health services in Tyrol: An analysis of epidemiological literature and administrative data from the Tyrolean health insurance	published	113b	2019	<a href="http://eprints.hta.lbg.ac.at/1181/">http://eprints.hta.lbg.ac.at/1181/</a>
Evaluation methods for benefit assessment of easily accessible outpatient health centres for vulnerable groups - Focus: homeless and uninsured persons	published	114	2019	<a href="http://eprints.hta.lbg.ac.at/1195/">http://eprints.hta.lbg.ac.at/1195/</a>
Transcatheter aortic valve implantation (TAVI) for the treatment of patients at intermediate surgical risk TRANSCATHETER AORTIC VALVE IMPLANTATION (TAVI)	published	115	2019	<a href="http://eprints.hta.lbg.ac.at/1188/">http://eprints.hta.lbg.ac.at/1188/</a>
C-reactive protein point-of-care testing (CRP POCT) to guide antibiotic prescribing in primary care settings for acute respiratory tract infections. EUnetHTA-Report	published	116	2019	<a href="http://eprints.hta.lbg.ac.at/1194/">http://eprints.hta.lbg.ac.at/1194/</a>
3D-Druck von maßgefertigten oder individualisierbaren Implantaten und Schnittschablonen: EUnetHTA-Report	published	117	2019	<a href="http://eprints.hta.lbg.ac.at/1209/">http://eprints.hta.lbg.ac.at/1209/</a>
Screening for Diabetes mellitus: guideline recommendations	published	118	2019	<a href="http://eprints.hta.lbg.ac.at/1213/">http://eprints.hta.lbg.ac.at/1213/</a>
Irreversible Elektroporation (IRE) bei Bauchspeicheldrüsen- und Leberkrebs. EUnetHTA-Report	published	119	2019	<a href="http://eprints.hta.lbg.ac.at/1211/">http://eprints.hta.lbg.ac.at/1211/</a>
Public & philanthropic financial contribution to the development of new drugs: Methodology & 3 Case Studies	published	120	2019	<a href="http://eprints.hta.lbg.ac.at/1214/">http://eprints.hta.lbg.ac.at/1214/</a>
Prevention of cervical cancer in Austria – Implementation of HPV testing into the existing screening programme	published	121	2019	<a href="http://eprints.hta.lbg.ac.at/1223/">http://eprints.hta.lbg.ac.at/1223/</a>
Rehabilitation for children and adolescents in Austria: A systematic analysis of evaluation methodologies	published	122	2019	<a href="http://eprints.hta.lbg.ac.at/1222/">http://eprints.hta.lbg.ac.at/1222/</a>
Screening programmes for children and adolescents aged 6-18 years, Part II	finished	123		not published
POCT/ Point of Care Tests: D-Dimer und Troponin	published	124	2019	<a href="http://eprints.hta.lbg.ac.at/1224/">http://eprints.hta.lbg.ac.at/1224/</a>
Minimum volume standards for quality assurance in day surgery	published	125	2019	<a href="http://eprints.hta.lbg.ac.at/1225/">http://eprints.hta.lbg.ac.at/1225/</a>
Health Services Research in Oncology: Patients with Non-small Cell Lung Cancer (NSCLC) treated with Anti-PD1/PD-L1 Therapy in Real-World Practice	published	126	2020	<a href="https://eprints.aihta.at/1227/">https://eprints.aihta.at/1227/</a>
Health Services Research in Oncology Part I: End-of-Life Care	published	127	2020	<a href="http://eprints.aihta.at/1233/">http://eprints.aihta.at/1233/</a>
Robotics and functional electrical stimulation for stroke rehabilitation	published	128	2020	<a href="https://eprints.aihta.at/1302/">https://eprints.aihta.at/1302/</a>
Home treatment in child and adolescent psychiatry: An analysis of effectiveness and integrated care	published	129	2020	<a href="http://eprints.aihta.at/1275/">http://eprints.aihta.at/1275/</a>
Molecular genetic diagnostics as a triage mechanism in cardiology using the example of familial hypercholesterolemia: Organisational and ethical implications (part 1) and economic effects (part 2)	published	130	2020	<a href="http://eprints.aihta.at/1281/">http://eprints.aihta.at/1281/</a>
Lung cancer screening in risk groups Systematic review(s) of effectiveness and utility (part 1)	published	132a	2020	<a href="http://eprints.aihta.at/1282/">http://eprints.aihta.at/1282/</a>
Lung cancer screening in risk groups Systematic review(s) of Costs and budgetary consequences (part 2)	published	132b	2020	<a href="https://eprints.aihta.at/1283/">https://eprints.aihta.at/1283/</a>
Effectiveness of music therapy	published	133	2020	<a href="http://eprints.aihta.at/1280/">http://eprints.aihta.at/1280/</a>

Title	Status	No.	Year	Download/Link
Framework for reimbursement decisions of digital health technologies (mHealth) and its (retrospective) application on selected examples	published	134	2020	<a href="https://eprints.aihta.at/1279">https://eprints.aihta.at/1279</a>
Epidemiology of long COVID: a preliminary report. German short version of the original KCE report	published	135a	2021	<a href="https://eprints.aihta.at/1321">https://eprints.aihta.at/1321</a>
Long COVID care pathways: a systematic review	published	135b	2021	<a href="https://eprints.aihta.at/1342">https://eprints.aihta.at/1342</a>
Evidence-based reimbursement processes in Europe Part 1: Reimbursement decisions for medical procedures in Austria. An analysis of factors – besides clinical evidence – influencing reimbursement decisions for the hospital benefit catalogue	ongoing	136		
Evidence-based reimbursement processes in Europe Part 2: A comparative analysis of selected medical devices in German and Austrian hospitals and possible influencing factors	ongoing	137		
(Good) practice organizational models using real-world evidence for public funding of high prized therapies	published	138	2021	<a href="https://eprints.aihta.at/1329">https://eprints.aihta.at/1329</a>
National strategies and programmes for preventing and managing non-communicable diseases in selected countries	published	139		<a href="https://eprints.aihta.at/1349/">https://eprints.aihta.at/1349/</a>
Contrasting evidence from pivotal trials with real world evidence for treatment with nivolumab in malignant melanoma.	published	140	2021	<a href="https://eprints.aihta.at/1341">https://eprints.aihta.at/1341</a>
Process and evaluation of digital health applications in the context of "Symptom Checkers"	published	141	2021	<a href="https://eprints.aihta.at/1348/">https://eprints.aihta.at/1348/</a>
The economic and societal dimension of parental mental illness	published	142	2021	<a href="https://eprints.aihta.at/1351/">https://eprints.aihta.at/1351/</a>
Telemonitoring in Austrian diabetes care: A systematic analysis of evaluation methodologies	published	143	2022	<a href="https://eprints.aihta.at/1370/">https://eprints.aihta.at/1370/</a>
Osteopathy: effectiveness and safety for musculoskeletal pain and overview of training and quality requirements	published	144	2022	<a href="https://eprints.aihta.at/1416">https://eprints.aihta.at/1416</a>
Risk-based breast cancer screening in Austria: a systematic analysis of predictive models to assess the individual breast cancer risk, their utility and applicability in breast cancer screening programs	published	145	2022	<a href="https://eprints.aihta.at/1402/">https://eprints.aihta.at/1402/</a>
CAR-T cell therapies (axicabtagen ciloleuce/Yescarta®) or tisagenlecleuce/Kymriah®): Contrasting pivotal studies with data from utility studies	published	146	2022	<a href="https://eprints.aihta.at/1415/">https://eprints.aihta.at/1415/</a>
Support for children with mentally ill parents in Tyrol: Summary results of the Village Project	ongoing	147		
Perinatal and infant mental health care models and pathways	published	148	2022	<a href="https://eprints.aihta.at/1420/">https://eprints.aihta.at/1420/</a>
Child and adolescent mental health care models	published	149	2022	<a href="https://eprints.aihta.at/1418/">https://eprints.aihta.at/1418/</a>
Quality Registries in Dementia Care: Mapping of Registries to improve Quality and Service Delivery	published	150	2022	<a href="https://eprints.aihta.at/1419/">https://eprints.aihta.at/1419/</a>
<b>Rapid Assessments</b>				
Drug eluting stents in comparison to uncoated stents in the treatment of cardiopathy	published	1	2006	<a href="http://eprints.hta.lbg.ac.at/34/">http://eprints.hta.lbg.ac.at/34/</a>
Avastin® for age-related macular degeneration	published	2	2007	<a href="http://eprints.hta.lbg.ac.at/718/">http://eprints.hta.lbg.ac.at/718/</a>
Rational Vaccination Policies - decision support. Review of International Literature for "Rational" Vaccination Policies	published	3	2008	<a href="http://eprints.hta.lbg.ac.at/761/">http://eprints.hta.lbg.ac.at/761/</a>
Sacral Nerve Stimulation for Fecal Incontinence	published	4	2011	<a href="http://eprints.hta.lbg.ac.at/925/">http://eprints.hta.lbg.ac.at/925/</a>
Avastin® for age-related macular degeneration: Gutachten zu Stand des Wissens	published	5	2012	<a href="http://eprints.hta.lbg.ac.at/989/">http://eprints.hta.lbg.ac.at/989/</a>
Hybrid-Operation rooms	published	6	2013	<a href="http://eprints.hta.lbg.ac.at/995/">http://eprints.hta.lbg.ac.at/995/</a>
Transparency: continuing medical education and NIS database	published	7a	2015	<a href="http://eprints.hta.lbg.ac.at/1053/">http://eprints.hta.lbg.ac.at/1053/</a>
Transparency: continuing medical education	published	7b	2015	<a href="http://eprints.hta.lbg.ac.at/1072/">http://eprints.hta.lbg.ac.at/1072/</a>
Transparency: continuing medical education/observational study and NIS database	published	7c	2016	<a href="http://eprints.hta.lbg.ac.at/1080">http://eprints.hta.lbg.ac.at/1080</a>
Pharma: Disclosure of transfers of value in austria 2015	published	7d	2017	<a href="http://eprints.hta.lbg.ac.at/1107/">http://eprints.hta.lbg.ac.at/1107/</a>
Drugs in Oncology: an overview of benefit and refund practices in Europe	published	8	2016	<a href="http://eprints.hta.lbg.ac.at/1091/">http://eprints.hta.lbg.ac.at/1091/</a>
HTAs on Medical Devices and Procedures in Europe: Timing, Risk-Classes, Product-Groups, Assessments	published	12	2016	<a href="http://eprints.hta.lbg.ac.at/1108/">http://eprints.hta.lbg.ac.at/1108/</a>
Importance and transparency of non-interventional drug studies (NIS) in selected countries: A comparison with Austria	published	7c/1. Update 2017	2017	<a href="http://eprints.hta.lbg.ac.at/1122/">http://eprints.hta.lbg.ac.at/1122/</a>
Sponsoring of Patient Initiatives in Austria 2015. Update of the Systematic Analysis 2014	published	7b/1. Update 2017	2017	<a href="http://eprints.hta.lbg.ac.at/1125/">http://eprints.hta.lbg.ac.at/1125/</a>
Sponsoring of Patient Initiatives in Austria 2016. Update of the Systematic Analysis 2015 and 2014	published	7b/2. Update 2017	2017	<a href="http://eprints.hta.lbg.ac.at/1132">http://eprints.hta.lbg.ac.at/1132</a>
MammaPrint® Added value of using the gene expression signature test MammaPrint® for adjuvant chemotherapy decision-making in early breast cancer. EunetHTA report	published	13	2018	<a href="http://eprints.hta.lbg.ac.at/1147">http://eprints.hta.lbg.ac.at/1147</a>
FoundationOne®CDx: Bestimmung von genetischen Profilen solider Tumore	published	14	2019	<a href="http://eprints.hta.lbg.ac.at/1215/">http://eprints.hta.lbg.ac.at/1215/</a>
Sponsoring of Patient Initiatives in Austria 2018. Update of the Systematic Analyses 2014, 2015 and 2016	published	7b/3. Update 2017	2019	<a href="http://eprints.hta.lbg.ac.at/1217/">http://eprints.hta.lbg.ac.at/1217/</a>
Pharma: Disclosure of transfers of value in austria 2018. Update of the systematic analysis 2015	published	7d/1. Update 2019	2019	<a href="http://eprints.hta.lbg.ac.at/1218/">http://eprints.hta.lbg.ac.at/1218/</a>
<b>Policy Briefs</b>				
Update 12 Monate Nachbeobachtung: Nusinersen bei Spinaler Muskelatrophie („late onset“) bei Kindern und Jugendlichen ≥ 6 Jahre	published	1	2020	<a href="http://eprints.aihta.at/1228/">http://eprints.aihta.at/1228/</a>
Covid-19: HSS/ Horizon Scanning Living Document (Part 1 & Part 2)	published	2	2020	<a href="http://eprints.aihta.at/1234/">http://eprints.aihta.at/1234/</a>
PET-Indikations	published	3	2020	<a href="http://eprints.aihta.at/1249/">http://eprints.aihta.at/1249/</a>
Update: Proton- and Carbon Ion therapy	published	4	2020	<a href="http://eprints.aihta.at/1245/">http://eprints.aihta.at/1245/</a>
Parent-Child-Pass Update 2020/21 – Screenings for mental health, nutrition and social competence – recommendations from evidence-based guidelines	published	5	2021	<a href="http://eprints.aihta.at/1303/">http://eprints.aihta.at/1303/</a>
Car-T Cell Therapies	published	6a	2020	<a href="http://eprints.aihta.at/1268/">http://eprints.aihta.at/1268/</a>
ATMPs and Gene Therapies	published	6b	2020	<a href="http://eprints.aihta.at/1269/">http://eprints.aihta.at/1269/</a>
Transparency: Sponsoring of patient initiatives, Update	published	7	2021	<a href="https://eprints.aihta.at/1308">https://eprints.aihta.at/1308</a>
Combinationtherapy Casirivimab plus Imdevimab (REGN-COV2) for the treatment of covid-19	published	8	2021	<a href="http://eprints.aihta.at/1313/">http://eprints.aihta.at/1313/</a>
Bamlanivimab monotherapy and as combination therapy (with etesevimab) for Covid-19	published	9	2021	<a href="http://eprints.aihta.at/1314/">http://eprints.aihta.at/1314/</a>
Nicht-Interventionelle Studien (NIS) in Österreich	published	10	2021	<a href="https://eprints.aihta.at/1333/">https://eprints.aihta.at/1333/</a>
Stool DNA testing for colorectal cancer (CRC) screening	published	11	2021	<a href="https://eprints.aihta.at/1335">https://eprints.aihta.at/1335</a>
≥ 12 Month Follow-Up of Patients with Spinal Muscular Atrophy (SMA) treated with Spinraza®, Zolgensma® or Combination Therapies	published	1/1. Update 2021	2021	<a href="https://eprints.aihta.at/1352">https://eprints.aihta.at/1352</a>

Title	Status	No.	Year	Download/Link
Regulation and financing of prenatal screening and diagnostic examinations for fetal anomalies in selected European countries	published	12	2022	<a href="https://eprints.aihta.at/1369/">https://eprints.aihta.at/1369/</a>
Car-T Cell Therapies	published	6a/Update 2022	2022	<a href="https://eprints.aihta.at/1368/">https://eprints.aihta.at/1368/</a>
ATMPs and Gene Therapies in Development. Horizon Scanning – Update 2022	published	6b/ update 2022	2022	<a href="https://eprints.aihta.at/1383">https://eprints.aihta.at/1383</a>
<b>Decision Support Documents</b>				
Photoselective vaporisation of the prostate in men with benign prostatic hyperplasia	published	1	2007	<a href="http://eprints.hta.lbg.ac.at/747/">http://eprints.hta.lbg.ac.at/747/</a>
Targeted radionuclide therapy with 90Y- and 177Lu-DOTATOC in patients with neuroendocrine tumors	published	2	2007	<a href="http://eprints.hta.lbg.ac.at/749/">http://eprints.hta.lbg.ac.at/749/</a>
Photodynamic therapy for the treatment of malignant stenosis in the alimentary tract	published	3	2007	<a href="http://eprints.hta.lbg.ac.at/51/">http://eprints.hta.lbg.ac.at/51/</a>
New minimally invasive methods in the treatment of stress urinary incontinence. Systematic review	published	6	2008	<a href="http://eprints.hta.lbg.ac.at/763/">http://eprints.hta.lbg.ac.at/763/</a>
LDL apheresis. Systematic review	published	7	2008	<a href="http://eprints.hta.lbg.ac.at/764/">http://eprints.hta.lbg.ac.at/764/</a>
Kyphoplasty and vertebroplasty for osteoporotic vertebral compression fractures. Systematic review	published	8	2008	<a href="http://eprints.hta.lbg.ac.at/770/">http://eprints.hta.lbg.ac.at/770/</a>
Percutaneous pulmonary valve implantation for right ventricular outflow tract dysfunction in patients with congenital heart defects. Systematic review	published	10	2008	<a href="http://eprints.hta.lbg.ac.at/768/">http://eprints.hta.lbg.ac.at/768/</a>
Selective Cell Apheresis in Inflammatory Bowel Disease	published	11	2008	<a href="http://eprints.hta.lbg.ac.at/792/">http://eprints.hta.lbg.ac.at/792/</a>
Rheopheresis in patients with age-related macular degeneration, sudden hearing loss or tinnitus, diabetes. Systematic review	published	12	2008	<a href="http://eprints.hta.lbg.ac.at/758/">http://eprints.hta.lbg.ac.at/758/</a>
Optical Coherence Tomography. Systematic review	published	13	2008	<a href="http://eprints.hta.lbg.ac.at/84/">http://eprints.hta.lbg.ac.at/84/</a>
Stent-grafting of the ascending aorta. Systematic review	published	14	2008	<a href="http://eprints.hta.lbg.ac.at/762/">http://eprints.hta.lbg.ac.at/762/</a>
Cardiac contractility modulation for heart failure. Systematic review	published	15	2008	<a href="http://eprints.hta.lbg.ac.at/769/">http://eprints.hta.lbg.ac.at/769/</a>
Aromatherapy for pain relief and psychological problems. Systematic review	published	16	2008	<a href="http://eprints.hta.lbg.ac.at/765/">http://eprints.hta.lbg.ac.at/765/</a>
Bach Flower Remedies for pain relief and psychological problems. Systematic review	published	17	2008	<a href="http://eprints.hta.lbg.ac.at/767/">http://eprints.hta.lbg.ac.at/767/</a>
Percutaneous aortic valve replacement. Systematic review	published	18	2008	<a href="http://eprints.hta.lbg.ac.at/766/">http://eprints.hta.lbg.ac.at/766/</a>
Enzyme Replacement Therapy for Lysosomal Storage Diseases	published	19	2008	<a href="http://eprints.hta.lbg.ac.at/812/">http://eprints.hta.lbg.ac.at/812/</a>
Endobronchial valve implantation for emphysema	finished	20	2008	not published
Chemonucleolysis and intradiscal electrotherapy (IDET). Systematic Review.	published	21a	2009	<a href="http://eprints.hta.lbg.ac.at/828/">http://eprints.hta.lbg.ac.at/828/</a>
Percutaneous nucleotomy and percutaneous laser disk decompression. Systematic Review.	published	21b	2009	<a href="http://eprints.hta.lbg.ac.at/830/">http://eprints.hta.lbg.ac.at/830/</a>
Injection therapies and radiofrequency for the treatment of chronic back pain. Systematic Review.	published	22	2009	<a href="http://eprints.hta.lbg.ac.at/831/">http://eprints.hta.lbg.ac.at/831/</a>
Intraoperative radiotherapy for primary breast cancer. Systematic Review.	published	23	2009	<a href="http://eprints.hta.lbg.ac.at/832/">http://eprints.hta.lbg.ac.at/832/</a>
Drug coated balloon catheter. Systematic Review.	published	24	2009	<a href="http://eprints.hta.lbg.ac.at/833/">http://eprints.hta.lbg.ac.at/833/</a>
Selective IgG Apheresis for ABO-incompatible kidney transplantation. Systematic Review.	published	25	2009	<a href="http://eprints.hta.lbg.ac.at/834/">http://eprints.hta.lbg.ac.at/834/</a>
Image guided radiotherapy using cone-beam computed tomography. Systematic Review.	published	26	2009	<a href="http://eprints.hta.lbg.ac.at/835/">http://eprints.hta.lbg.ac.at/835/</a>
Pumpless extracorporeal lung assist (PECLA). Systematic Review.	published	27	2009	<a href="http://eprints.hta.lbg.ac.at/836/">http://eprints.hta.lbg.ac.at/836/</a>
Retroluminal transobturatoric reposition sling for the treatment of stress urinary incontinence in men. Systematic Review.	published	30	2009	<a href="http://eprints.hta.lbg.ac.at/837/">http://eprints.hta.lbg.ac.at/837/</a>
Stent-grafting of the ascending aorta. Systematic review	published	14/ Update 2009	2009	<a href="http://eprints.hta.lbg.ac.at/895/">http://eprints.hta.lbg.ac.at/895/</a>
Cardiac contractility modulation for heart failure. Systematic review	published	15/ Update 2009	2009	<a href="http://eprints.hta.lbg.ac.at/896/">http://eprints.hta.lbg.ac.at/896/</a>
Percutaneous aortic valve replacement. Systematic review	published	18/ Update 2009	2009	<a href="http://eprints.hta.lbg.ac.at/897/">http://eprints.hta.lbg.ac.at/897/</a>
Endobronchial valve implantation for emphysema. Systematic review	finished	20/ Update 2009	2009	not published
Bioresonance for allergies, atopic dermatitis, non-organic gastrointestinal complaints, pain and rheumatic diseases.	published	31	2009	<a href="http://eprints.hta.lbg.ac.at/842/">http://eprints.hta.lbg.ac.at/842/</a>
Colon Hydrotherapy for defecation disorders. Systematic Review	published	32	2009	<a href="http://eprints.hta.lbg.ac.at/827/">http://eprints.hta.lbg.ac.at/827/</a>
International comparison of antenatal care in pregnant women	published	33	2009	<a href="http://eprints.hta.lbg.ac.at/826/">http://eprints.hta.lbg.ac.at/826/</a>
Autologous Chondrocyte Implantation	published	34	2009	<a href="http://eprints.hta.lbg.ac.at/865/">http://eprints.hta.lbg.ac.at/865/</a>
New influenza (swine flu) – data & facts for decision support.	published	35	2009	<a href="http://eprints.hta.lbg.ac.at/845/">http://eprints.hta.lbg.ac.at/845/</a>
Hyperthermia	published	36	2010	<a href="http://eprints.hta.lbg.ac.at/883/">http://eprints.hta.lbg.ac.at/883/</a>
High intensity focused ultrasound (HIFU) for the treatment of prostate cancer	published	37	2010	<a href="http://eprints.hta.lbg.ac.at/887/">http://eprints.hta.lbg.ac.at/887/</a>
Artificial disc replacement	published	38	2010	<a href="http://eprints.hta.lbg.ac.at/886/">http://eprints.hta.lbg.ac.at/886/</a>
Laser angioplasty of coronary arteries	published	39	2010	<a href="http://eprints.hta.lbg.ac.at/885/">http://eprints.hta.lbg.ac.at/885/</a>
Radionuclide therapy - 90Yttrium and 177Lutetium somatostatin analogues for the treatment of inoperable neuroendocrine tumors	published	40	2010	<a href="http://eprints.hta.lbg.ac.at/889/">http://eprints.hta.lbg.ac.at/889/</a>
Mitral valve repair using a mitral clip	published	41	2010	<a href="http://eprints.hta.lbg.ac.at/888/">http://eprints.hta.lbg.ac.at/888/</a>
Kyphoplasty and vertebroplasty for osteoporotic vertebral compression fractures. Systematic review	published	8/ Update 2010	2010	<a href="http://eprints.hta.lbg.ac.at/890/">http://eprints.hta.lbg.ac.at/890/</a>
Stent-grafting of the ascending aorta. Systematic review	published	14/ Update 2010	2010	<a href="http://eprints.hta.lbg.ac.at/892/">http://eprints.hta.lbg.ac.at/892/</a>
Cardiac contractility modulation for heart failure. Systematic review	published	15/ Update 2010	2010	<a href="http://eprints.hta.lbg.ac.at/893/">http://eprints.hta.lbg.ac.at/893/</a>
Percutaneous aortic valve replacement. Systematic review	published	18/ Update 2010	2010	<a href="http://eprints.hta.lbg.ac.at/894/">http://eprints.hta.lbg.ac.at/894/</a>
Endobronchial valve implantation for emphysema. Systematic review	published	20/ Update 2010	2010	<a href="http://eprints.hta.lbg.ac.at/891/">http://eprints.hta.lbg.ac.at/891/</a>
Anti-Vascular-Endothelial-Growth-Factor (anti-VEGF) for the treatment of diabetic macular edema. German version.	published	43	2011	<a href="http://eprints.hta.lbg.ac.at/916/">http://eprints.hta.lbg.ac.at/916/</a>
Anti-Vascular-Endothelial-Growth-Factor (anti-VEGF) for the treatment of diabetic macular edema. English version.	published	43	2011	<a href="http://eprints.hta.lbg.ac.at/917/">http://eprints.hta.lbg.ac.at/917/</a>

Title	Status	No.	Year	Download/Link
Percutaneous Left Atrial Appendage Closure for the prevention of thrombo-embolic events in patients with atrial fibrillation	published	44	2011	<a href="http://eprints.hta.lbg.ac.at/918/">http://eprints.hta.lbg.ac.at/918/</a>
Renal denervation in patients with essential hypertension	published	45	2011	<a href="http://eprints.hta.lbg.ac.at/919/">http://eprints.hta.lbg.ac.at/919/</a>
Mechanical percutaneous transluminal cerebral clot retrieval in acute ischemic stroke	published	46	2011	<a href="http://eprints.hta.lbg.ac.at/920/">http://eprints.hta.lbg.ac.at/920/</a>
Selective internal radiation therapy using yttrium-90 microspheres for the treatment of primary or metastatic liver malignancies. German version.	published	47	2011	<a href="http://eprints.hta.lbg.ac.at/921/">http://eprints.hta.lbg.ac.at/921/</a>
Selective internal radiation therapy using yttrium-90 microspheres for the treatment of primary or metastatic liver malignancies. English version.	published	47	2011	<a href="http://eprints.hta.lbg.ac.at/922/">http://eprints.hta.lbg.ac.at/922/</a>
Percutaneous aortic valve replacement with a side note to hybrid operating rooms	published	18/ Update 2011	2011	<a href="http://eprints.hta.lbg.ac.at/923/">http://eprints.hta.lbg.ac.at/923/</a>
Outpatient cardiac rehabilitation. Part 4: Options for carrying out a prospective study	published	48	2011	<a href="http://eprints.hta.lbg.ac.at/928/">http://eprints.hta.lbg.ac.at/928/</a>
Radiofrequency ablation for hepatocellular carcinoma and colorectal liver metastases	published	49	2011	<a href="http://eprints.hta.lbg.ac.at/933/">http://eprints.hta.lbg.ac.at/933/</a>
Outpatient cardiac rehabilitation Part 5: Preparation of the study protocol for the planned prospective study	published	50	2012	<a href="http://eprints.hta.lbg.ac.at/971/">http://eprints.hta.lbg.ac.at/971/</a>
Training therapy in physical medicine – Systematic Review	published	51	2012	<a href="http://eprints.hta.lbg.ac.at/950/">http://eprints.hta.lbg.ac.at/950/</a>
Exercise therapy (Krankengymnastik/ Heilgymnastik) in physical medicine	published	52	2012	<a href="http://eprints.hta.lbg.ac.at/951/">http://eprints.hta.lbg.ac.at/951/</a>
Radiofrequency ablation of tumors of the lung and mediastinal lymph nodes	published	53	2012	<a href="http://eprints.hta.lbg.ac.at/957/">http://eprints.hta.lbg.ac.at/957/</a>
Radiofrequency ablation of bone tumors (osteoid-osteoma and osseous metastases)	published	54	2012	<a href="http://eprints.hta.lbg.ac.at/958/">http://eprints.hta.lbg.ac.at/958/</a>
Radiofrequency ablation of head and neck cancer	published	55	2012	<a href="http://eprints.hta.lbg.ac.at/959/">http://eprints.hta.lbg.ac.at/959/</a>
Radiofrequency ablation of benign and malign nodules of endocrine organs (thyroid gland and adrenal gland)	published	56	2012	<a href="http://eprints.hta.lbg.ac.at/960/">http://eprints.hta.lbg.ac.at/960/</a>
Radiofrequency ablation of breast cancer	published	57	2012	<a href="http://eprints.hta.lbg.ac.at/961/">http://eprints.hta.lbg.ac.at/961/</a>
Radiofrequency ablation of primary tumors of the gastrointestinal tract (colorectal and pancreatic cancer)	published	58	2012	<a href="http://eprints.hta.lbg.ac.at/962/">http://eprints.hta.lbg.ac.at/962/</a>
Radiofrequency ablation of tumors of the urogenital tract (renal cell carcinoma, prostate cancer, uterine leiomyoma)	published	59	2012	<a href="http://eprints.hta.lbg.ac.at/963/">http://eprints.hta.lbg.ac.at/963/</a>
Sling suspension in male urinary incontinence	published	60	2012	<a href="http://eprints.hta.lbg.ac.at/964/">http://eprints.hta.lbg.ac.at/964/</a>
Stem cell therapy for urinary stress incontinence	published	6/Update 2012	2012	<a href="http://eprints.hta.lbg.ac.at/965/">http://eprints.hta.lbg.ac.at/965/</a>
Mitral valve repair using a mitral clip	published	41/Update 2012	2012	<a href="http://eprints.hta.lbg.ac.at/967/">http://eprints.hta.lbg.ac.at/967/</a>
Intraoperative radiotherapy for primary breast cancer. Systematic Review.	published	23/Update 2012	2012	<a href="http://eprints.hta.lbg.ac.at/966/">http://eprints.hta.lbg.ac.at/966/</a>
Renal denervation in patients with essential hypertension	published	45/update 2012	2012	<a href="http://eprints.hta.lbg.ac.at/968/">http://eprints.hta.lbg.ac.at/968/</a>
HIV testing in healthy subjects: an international comparison Austria	published	61	2012	<a href="http://eprints.hta.lbg.ac.at/979/">http://eprints.hta.lbg.ac.at/979/</a>
Extracorporeal shock wave therapy (ESWT) of non-union or delayed union of fractures	published	62	2012	<a href="http://eprints.hta.lbg.ac.at/975/">http://eprints.hta.lbg.ac.at/975/</a>
Hyperthermia	published	36/Update 2012	2012	<a href="http://eprints.hta.lbg.ac.at/986/">http://eprints.hta.lbg.ac.at/986/</a>
Evidence overview of therapeutic hypothermia	published	63	2012	<a href="http://eprints.hta.lbg.ac.at/985/">http://eprints.hta.lbg.ac.at/985/</a>
Percutaneous coronary intervention for chronic total occlusion	published	64	2013	<a href="http://eprints.hta.lbg.ac.at/1000/">http://eprints.hta.lbg.ac.at/1000/</a>
Implantation of a lumbar artificial endoprosthesis (anuloplasty/ anular repair device)	published	65	2013	<a href="http://eprints.hta.lbg.ac.at/1001/">http://eprints.hta.lbg.ac.at/1001/</a>
Repair of cartilage defects via matrix-associated autologous chondrocyte immigration	published	66	2013	<a href="http://eprints.hta.lbg.ac.at/1002/">http://eprints.hta.lbg.ac.at/1002/</a>
Duodeno-jejunal bypass liner (DJB) for patients with obesity	published	67	2013	<a href="http://eprints.hta.lbg.ac.at/1008/">http://eprints.hta.lbg.ac.at/1008/</a>
Percutaneous transluminal angioplasty (PTA) of periphery arteries with drug-eluting balloon (DEB)	published	68	2013	<a href="http://eprints.hta.lbg.ac.at/1003/">http://eprints.hta.lbg.ac.at/1003/</a>
Endovascular repair of aortic aneurysms	published	69	2013	<a href="http://eprints.hta.lbg.ac.at/1004/">http://eprints.hta.lbg.ac.at/1004/</a>
Percutaneous transcatheter closure of prosthetic mitral and aortic paravalvular leaks	published	70	2013	<a href="http://eprints.hta.lbg.ac.at/1005/">http://eprints.hta.lbg.ac.at/1005/</a>
Percutaneous transluminal septal myocardial ablation (PTSCA) in hypertrophic obstructive cardiomyopathy (HOCM)	published	71	2013	<a href="http://eprints.hta.lbg.ac.at/1006/">http://eprints.hta.lbg.ac.at/1006/</a>
Percutaneous transluminal coronary angioplasty (PTCA) with paclitaxel-coated drug-eluting balloon (DEB) (1st Update)	published	24/Update 2013	2013	<a href="http://eprints.hta.lbg.ac.at/1007/">http://eprints.hta.lbg.ac.at/1007/</a>
Assessment – APPRAISAL – Decision: (Good) Practice examples and recommendations	published	72	2014	<a href="http://eprints.hta.lbg.ac.at/1036/">http://eprints.hta.lbg.ac.at/1036/</a>
Zostavax® for prevention of Herpes Zoster	published	73	2013	<a href="http://eprints.hta.lbg.ac.at/1013/">http://eprints.hta.lbg.ac.at/1013/</a>
Hyperthermic intraperitoneal chemotherapy (HIPEC) for treatment of peritoneal carcinosis	published	74	2014	<a href="http://eprints.hta.lbg.ac.at/1031/">http://eprints.hta.lbg.ac.at/1031/</a>
Percutaneous transluminal angioplasty (PTA) with drug-eluting stents	published	75	2014	<a href="http://eprints.hta.lbg.ac.at/1032/">http://eprints.hta.lbg.ac.at/1032/</a>
Endobronchial valves in emphysema	published	20/Update 2014	2014	<a href="http://eprints.hta.lbg.ac.at/1028/">http://eprints.hta.lbg.ac.at/1028/</a>
Percutaneous left atrial appendage closure	published	44/Update 2014	2014	<a href="http://eprints.hta.lbg.ac.at/1029/">http://eprints.hta.lbg.ac.at/1029/</a>
Stereotactic Radiofrequency Ablation (SRFA) in hepatocellular carcinoma	published	76	2014	<a href="http://eprints.hta.lbg.ac.at/1030/">http://eprints.hta.lbg.ac.at/1030/</a>
Biomarker guidance	published	77	2014	<a href="http://eprints.hta.lbg.ac.at/1041/">http://eprints.hta.lbg.ac.at/1041/</a>
Re-orientation of the Austrian parent-child preventive care programme Part 10: further development of the mother-child-pass. Scientific support of the appraisal process	published	78	2014	<a href="http://eprints.hta.lbg.ac.at/1039/">http://eprints.hta.lbg.ac.at/1039/</a>
Vaccination against Human Papillomavirus (HPV). Decision Support for adolescent girls and women/ mothers	finished	79	2014	not published
Outpatient cardiac rehabilitation. Part 6a: Multi-centre, prospective cohort study with two control groups (with/without phase III). Baseline characteristics.	finished	80	2014	not published
Fully bioresorbable scaffolds for coronary artery disease: Systematic Review	published	81	2015	<a href="http://eprints.hta.lbg.ac.at/1060/">http://eprints.hta.lbg.ac.at/1060/</a>
Transcatheter mitral valve-in-valve implantation (TMVVI)	published	82	2015	<a href="http://eprints.hta.lbg.ac.at/1058/">http://eprints.hta.lbg.ac.at/1058/</a>
Endovascular embolisation of intracranial aneurysms with Flow Diverter	published	83	2015	<a href="http://eprints.hta.lbg.ac.at/1054/">http://eprints.hta.lbg.ac.at/1054/</a>
Defibrotide for hepatic veno-occlusive disease	published	84	2015	<a href="http://eprints.hta.lbg.ac.at/1061/">http://eprints.hta.lbg.ac.at/1061/</a>
Intracorneal ring segments for keratoconus	published	85	2015	<a href="http://eprints.hta.lbg.ac.at/1055/">http://eprints.hta.lbg.ac.at/1055/</a>



Title	Status	No.	Year	Download/Link
Neurostimulation for cluster headache	published	86	2015	<a href="http://eprints.hta.lbg.ac.at/1062/">http://eprints.hta.lbg.ac.at/1062/</a>
Local injection therapy with bulking agents for faecal incontinence	published	87	2015	<a href="http://eprints.hta.lbg.ac.at/1059/">http://eprints.hta.lbg.ac.at/1059/</a>
Percutaneous left atrial appendage closure (2.Update 2015)	published	44/Update 2015	2015	<a href="http://eprints.hta.lbg.ac.at/1056/">http://eprints.hta.lbg.ac.at/1056/</a>
Percutaneous transluminal angioplasty (PTA) of periphery arteries with drug-eluting balloon (DEB) (1.Update 2015)	published	68/Update 2015	2015	<a href="http://eprints.hta.lbg.ac.at/1057/">http://eprints.hta.lbg.ac.at/1057/</a>
Hadron therapy in children. Evidence synthesis to 15 pediatric tumors	published	88	2015	<a href="http://eprints.hta.lbg.ac.at/1049/">http://eprints.hta.lbg.ac.at/1049/</a>
Biodegradable stents for the treatment of refractory or recurrent benign oesophageal Stenosis: German summary to EUnetHTA-report	published	89	2015	<a href="http://eprints.hta.lbg.ac.at/1067/">http://eprints.hta.lbg.ac.at/1067/</a>
Background Analysis for National HTA Strategy for Lithuania: Focus on Medical Devices	published	90	2015	<a href="http://eprints.hta.lbg.ac.at/1063/">http://eprints.hta.lbg.ac.at/1063/</a>
HTA Strategy for Lithuania	published	90a	2015	<a href="http://eprints.hta.lbg.ac.at/1064/">http://eprints.hta.lbg.ac.at/1064/</a>
Balloon Eustachian Tuboplasty for the treatment of Eustachian tube dysfunction: German summary to EUnetHTA-report	published	91	2015	<a href="http://eprints.hta.lbg.ac.at/1073/">http://eprints.hta.lbg.ac.at/1073/</a>
Outpatient neurological rehabilitation: goal attainment in stroke patients. Systematic review.	published	92	2015	<a href="http://eprints.hta.lbg.ac.at/1071/">http://eprints.hta.lbg.ac.at/1071/</a>
Percutaneous mitral repair with chronic mitral insufficiency (Mitralclip®, Carillon®, NeoChord DS1000) . German Executive summary of the same EUnetHTA report	published	93	2015	<a href="http://eprints.hta.lbg.ac.at/1075/">http://eprints.hta.lbg.ac.at/1075/</a>
Mechanical thrombectomy in acute ischemic stroke. German Executive summary of the same report EUnetHTA	published	94	2016	<a href="http://eprints.hta.lbg.ac.at/1081/">http://eprints.hta.lbg.ac.at/1081/</a>
Screening, diagnostic testing and therapeutic indication for occupational therapy in children and adolescents with Developmental Coordination Disorder	published	96	2016	<a href="http://eprints.hta.lbg.ac.at/1092/">http://eprints.hta.lbg.ac.at/1092/</a>
Leadless pacemakers for right ventricle pacing	published	97	2016	<a href="http://eprints.hta.lbg.ac.at/1094/">http://eprints.hta.lbg.ac.at/1094/</a>
Autologous matrix-induced chondrogenesis for cartilage repair	published	98	2016	<a href="http://eprints.hta.lbg.ac.at/1095/">http://eprints.hta.lbg.ac.at/1095/</a>
Radiofrequency denervation for low back pain	published	99	2016	<a href="http://eprints.hta.lbg.ac.at/1096/">http://eprints.hta.lbg.ac.at/1096/</a>
Hypoglossal nerve stimulation for obstructive sleep apnoe	published	100	2016	<a href="http://eprints.hta.lbg.ac.at/1097/">http://eprints.hta.lbg.ac.at/1097/</a>
Magnetic esophageal ring for gastroesophageal reflux disease	published	101	2016	<a href="http://eprints.hta.lbg.ac.at/1098/">http://eprints.hta.lbg.ac.at/1098/</a>
Percutaneous transluminal coronary angioplasty with drug-eluting balloon	published	24/ Update 2016	2016	<a href="http://eprints.hta.lbg.ac.at/1093/">http://eprints.hta.lbg.ac.at/1093/</a>
Hepatitis C virus screening in hospitals	published	102	2016	<a href="http://eprints.hta.lbg.ac.at/1103/">http://eprints.hta.lbg.ac.at/1103/</a>
Portable cardioverter defibrillator therapy for primary and secondary prevention of sudden cardiac arrest	published	103	2016	<a href="http://eprints.hta.lbg.ac.at/1109/">http://eprints.hta.lbg.ac.at/1109/</a>
Electric stimulation therapy (EST) in patients with gastroesophageal reflux disease (GERD)	published	104	2017	<a href="http://eprints.hta.lbg.ac.at/1128/">http://eprints.hta.lbg.ac.at/1128/</a>
Prostate artery embolisation for benign prostatic hyperplasia	published	105	2017	<a href="http://eprints.hta.lbg.ac.at/1118/">http://eprints.hta.lbg.ac.at/1118/</a>
Extracorporeal cytokine haemadsorption in patients with sepsis or SIRS	published	106	2017	<a href="http://eprints.hta.lbg.ac.at/1129/">http://eprints.hta.lbg.ac.at/1129/</a>
Repetitive transcranial magnetic stimulation for treatment-resistant major depression	published	107	2017	<a href="http://eprints.hta.lbg.ac.at/1130/">http://eprints.hta.lbg.ac.at/1130/</a>
Radiofrequency ablation for metastatic spinal lesions	published	108	2017	<a href="http://eprints.hta.lbg.ac.at/1131/">http://eprints.hta.lbg.ac.at/1131/</a>
Percutaneous disc volume reduction with focus on chemonucleolysis	published	21 /Update 2017	2017	<a href="http://eprints.hta.lbg.ac.at/1126/">http://eprints.hta.lbg.ac.at/1126/</a>
Leadless pacemakers for right ventricle pacing	published	97/Update 2017	2017	<a href="http://eprints.hta.lbg.ac.at/1127/">http://eprints.hta.lbg.ac.at/1127/</a>
Endobronchial valve implantation for emphysema	published	20/4.Update 2018	2018	<a href="http://eprints.hta.lbg.ac.at/1166/">http://eprints.hta.lbg.ac.at/1166/</a>
High intensity focused ultrasound (HIFU) for the treatment of prostate cancer	published	37/1. Update 2018	2018	<a href="http://eprints.hta.lbg.ac.at/1167/">http://eprints.hta.lbg.ac.at/1167/</a>
Left Atrial Appendage Closure for the prevention of thrombo-embolic events in patients with atrial fibrillation	published	44/3. Update 2018	2018	<a href="http://eprints.hta.lbg.ac.at/1168/">http://eprints.hta.lbg.ac.at/1168/</a>
Subcutaneous implantable cardioverter defibrillator (ICD)	published	109	2018	<a href="http://eprints.hta.lbg.ac.at/1169/">http://eprints.hta.lbg.ac.at/1169/</a>
Lymphovenous anastomoses in patients with primary and secondary lymphedema	published	110	2018	<a href="http://eprints.hta.lbg.ac.at/1170/">http://eprints.hta.lbg.ac.at/1170/</a>
Allogeneic mesenchymal stem cells for Crohn's disease-associated complex perianal fistulas	published	111	2018	<a href="http://eprints.hta.lbg.ac.at/1171/">http://eprints.hta.lbg.ac.at/1171/</a>
Meniscal allograft transplantation	published	112	2018	<a href="http://eprints.hta.lbg.ac.at/1172/">http://eprints.hta.lbg.ac.at/1172/</a>
Baroreceptor activation therapy for treatment-resistant hypertension	published	113	2018	<a href="http://eprints.hta.lbg.ac.at/1173/">http://eprints.hta.lbg.ac.at/1173/</a>
External stimulation of the trigeminal nerve for the prevention and treatment of episodic and chronic migraine (Cefaly)	published	114	2018	<a href="http://eprints.hta.lbg.ac.at/1177/">http://eprints.hta.lbg.ac.at/1177/</a>
Wearable cardioverter-defibrillator (WCD) therapy as prevention of sudden cardiac death in patients at risk - Update 2018	published	103/Update 2018	2019	<a href="http://eprints.hta.lbg.ac.at/1186/">http://eprints.hta.lbg.ac.at/1186/</a>
Osteochondral Allograft Transplantation (knee or other joints)	published	115	2019	<a href="http://eprints.hta.lbg.ac.at/1173/">http://eprints.hta.lbg.ac.at/1173/</a>
Allograft for anterior and posterior cruciate ligament reconstruction	published	116	2019	<a href="http://eprints.hta.lbg.ac.at/1177/">http://eprints.hta.lbg.ac.at/1177/</a>
Human dermal allograft for reconstruction of rotator cuff tears	published	117	2019	<a href="http://eprints.hta.lbg.ac.at/1186/">http://eprints.hta.lbg.ac.at/1186/</a>
Lu-177-labeled Prostate-Specific Membrane Antigen Inhibitor Therapy in Patients with Castration-Resistant metastatic Prostate Cancer	published	118	2019	<a href="http://eprints.hta.lbg.ac.at/1204/">http://eprints.hta.lbg.ac.at/1204/</a>
Radiofrequency denervation for lumbar and cervical facet joint pain	published	99/Update 2019	2019	<a href="http://eprints.hta.lbg.ac.at/1205/">http://eprints.hta.lbg.ac.at/1205/</a>
(Single-step) scaffold-based cartilage repair in the knee	published	98/Update 2019	2019	<a href="http://eprints.hta.lbg.ac.at/1206/">http://eprints.hta.lbg.ac.at/1206/</a>
Implantation of a lumbar artificial endoprosthesis (anuloplasty/ anular repair device)	published	65/ Update 2019	2019	<a href="http://eprints.hta.lbg.ac.at/1207/">http://eprints.hta.lbg.ac.at/1207/</a>
Implantation of a completely bioresorbable stent into the coronary vessels	published	81/Update 2019	2019	<a href="http://eprints.hta.lbg.ac.at/1200/">http://eprints.hta.lbg.ac.at/1200/</a>
Upper airway stimulation for moderate-to-severe sleep apnea	published	100/Update 2019	2019	<a href="http://eprints.hta.lbg.ac.at/1201/">http://eprints.hta.lbg.ac.at/1201/</a>
Bioresorbable stents for the treatment of cardiovascular indications (coronary artery disease). EUnetHTA-Report	published	81/1.Update 2019	2019	<a href="http://eprints.hta.lbg.ac.at/1201/">http://eprints.hta.lbg.ac.at/1201/</a>
Telemontoring and pulmonanry artery pressure-guided treatment of heart failure	published	119	2020	<a href="http://eprints.aihta.at/1254/">http://eprints.aihta.at/1254/</a>
Ultrasound-guided transcervical Radiofrequency ablation of Myoma	published	120	2020	<a href="http://eprints.aihta.at/1255/">http://eprints.aihta.at/1255/</a>
Leadless Pacemakers for Right Ventricle Pacing	published	97/Update 2019	2020	<a href="http://eprints.aihta.at/1252/">http://eprints.aihta.at/1252/</a>
Extracorporeal cytokine headsorption	published	106/Update 2019	2020	<a href="http://eprints.aihta.at/1253/">http://eprints.aihta.at/1253/</a>

Title	Status	No.	Year	Download/Link
Percutaneous transvascular implantation of a coronary sinus constricting stent	published	121	2020	<a href="http://eprints.aihta.at/1256">http://eprints.aihta.at/1256</a>
Radiofrequency-Induced Intravesical Chemohyperthermia for Non-Muscle-Invasive Bladder Cancer	published	122	2020	<a href="http://eprints.aihta.at/1258">http://eprints.aihta.at/1258</a>
Photodynamic therapy in prostate cancer with padeliporfin (TOOKAD)	published	123	2020	<a href="http://eprints.aihta.at/1258">http://eprints.aihta.at/1258</a>
ercutaneous left ventricular assist devices: micro-axial flow pumps	published	124	2021	<a href="https://eprints.aihta.at/1323">https://eprints.aihta.at/1323</a>
Liposuction for surgical therapy of lipoeidema	published	125	2021	<a href="https://eprints.aihta.at/1324">https://eprints.aihta.at/1324</a>
Triphasic biomaterial for augmentation of the osteoporotic femoral neck	published	126	2021	<a href="https://eprints.aihta.at/1325">https://eprints.aihta.at/1325</a>
Endoscopic plication therapy in patients with gastroesophageal reflux disease (GERD)	published	127	2021	<a href="https://eprints.aihta.at/1326">https://eprints.aihta.at/1326</a>
Allogenic bone screw Shark Screw® in patients with hallux valgus or scaphoid fractures/pseudarthroses	published	128	2021	<a href="https://eprints.aihta.at/1327">https://eprints.aihta.at/1327</a>
Comparative effectiveness of surgical techniques and devices for the treatment of benign prostatic hyperplasia	published	129	2021	<a href="https://eprints.aihta.at/1328">https://eprints.aihta.at/1328</a>
Implantation of Bulking Agents for Faecal Incontinence (1st Update)	published	87/1. Update	2021	<a href="https://eprints.aihta.at/1322">https://eprints.aihta.at/1322</a>
Percutaneous coronary interventions (PCI) for chronic total occlusion. Update 2022	published	64/Update 2022	2022	<a href="https://eprints.aihta.at/1386">https://eprints.aihta.at/1386</a>
Upper airway stimulation for moderate-to-severe sleep apnea. Update 2022	published	100/Update 2022	2022	<a href="https://eprints.aihta.at/1387">https://eprints.aihta.at/1387</a>
Subcutaneous implantable cardioverter defibrillator (ICD)	published	109/Update 2022	2022	<a href="https://eprints.aihta.at/1388">https://eprints.aihta.at/1388</a>
Percutaneous Transvascular Implantation of a Coronary Sinus Reducing Stent	published	121/Update 2022	2022	<a href="https://eprints.aihta.at/1389">https://eprints.aihta.at/1389</a>
Hepatic and portal vein embolization prior to major hepatectomy	published	130	2022	<a href="https://eprints.aihta.at/1390">https://eprints.aihta.at/1390</a>
Ultrasound-guided microwave ablation for liver tumors	published	131	2022	<a href="https://eprints.aihta.at/1391">https://eprints.aihta.at/1391</a>
HIS Bundle Pacing for patients requiring permanent pacemaker	published	132	2022	<a href="https://eprints.aihta.at/1392">https://eprints.aihta.at/1392</a>
Chemosaturation with percutaneous hepatic perfusions for patients with liver metastases	published	133	2022	<a href="https://eprints.aihta.at/1393">https://eprints.aihta.at/1393</a>
Lower Esophageal Sphincter Devices for Laparoscopic Surgery in Patients with Gastroesophageal Reflux Disease (GERD): magnetic sphincter augmentation device (MSAD) (Update 101), electric stimulation therapy (update 104) RefluxStop™ (new)	published	134	2022	<a href="https://eprints.aihta.at/1394">https://eprints.aihta.at/1394</a>
Wearable cardioverter-defibrillator (WCD) therapy as prevention of sudden cardiac death in patients at risk – Update 2022	published	103/2. Update 2022	2022	<a href="https://eprints.aihta.at/1407">https://eprints.aihta.at/1407</a>
<b>Decision Support Documents: Horizon Scanning in Oncology</b>				
Azacitidine (Vidaza®) for the treatment of myelodysplastic syndromes	published	1	2009	<a href="http://eprints.hta.lbg.ac.at/852/">http://eprints.hta.lbg.ac.at/852/</a>
Cetuximab (Erbix®) in EGFR-expressing Non-Small Cell Lung Cancer	published	2	2009	<a href="http://eprints.hta.lbg.ac.at/856/">http://eprints.hta.lbg.ac.at/856/</a>
Everolimus (Afinitor®) for advanced/metastatic kidney cancer	published	3	2009	<a href="http://eprints.hta.lbg.ac.at/857/">http://eprints.hta.lbg.ac.at/857/</a>
Rituximab (Rituxan®/MabThera®) for the first- and second-line treatment of chronic lymphocytic leukaemia	published	4	2009	<a href="http://eprints.hta.lbg.ac.at/860/">http://eprints.hta.lbg.ac.at/860/</a>
Ibrutinomab tiuxetan (Zevalin®) as consolidation therapy after first remission in patients with follicular lymphoma	published	5	2009	<a href="http://eprints.hta.lbg.ac.at/861/">http://eprints.hta.lbg.ac.at/861/</a>
Gefitinib (Iressa®) for the first-line treatment of non-small cell lung cancer	published	6	2010	<a href="http://eprints.hta.lbg.ac.at/868/">http://eprints.hta.lbg.ac.at/868/</a>
Trabectedin (Yondelis®) for second-line recurrent platinum-sensitive ovarian cancer	published	7	2010	<a href="http://eprints.hta.lbg.ac.at/869/">http://eprints.hta.lbg.ac.at/869/</a>
Plerixafor (Mozobil®) for autologous stem cell transplantation in patients with lymphoma and multiple myeloma	published	8	2010	<a href="http://eprints.hta.lbg.ac.at/878/">http://eprints.hta.lbg.ac.at/878/</a>
Lapatinib ditosylate (Tyverb/Tykerb®) as first-line therapy for the treatment of advanced/metastatic breast cancer	published	9	2010	<a href="http://eprints.hta.lbg.ac.at/882/">http://eprints.hta.lbg.ac.at/882/</a>
Bendamustine (Ribomustin®/Treanda®/ Levact®) for indolent non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukaemia (CLL) and multiple myeloma	published	10	2010	<a href="http://eprints.hta.lbg.ac.at/884/">http://eprints.hta.lbg.ac.at/884/</a>
Panitumumab (Vectibix®) for the first-line treatment of metastatic colorectal cancer	published	11	2010	<a href="http://eprints.hta.lbg.ac.at/880/">http://eprints.hta.lbg.ac.at/880/</a>
Trastuzumab (Herceptin®) in addition to standard chemotherapy as first-line therapy for advanced gastric cancer	published	12	2010	<a href="http://eprints.hta.lbg.ac.at/881/">http://eprints.hta.lbg.ac.at/881/</a>
Pazopanib (Votrient®) for the treatment of locally advanced and/or metastatic renal cell carcinoma	published	13	2010	<a href="http://eprints.hta.lbg.ac.at/902/">http://eprints.hta.lbg.ac.at/902/</a>
Ipilimumab for pre-treated patients with advanced/metastatic melanoma	published	14	2011	<a href="http://eprints.hta.lbg.ac.at/905/">http://eprints.hta.lbg.ac.at/905/</a>
Nilotinib (Tasigna®) for the 1st-line treatment of Philadelphia chromosome positive chronic myeloid leukemia in the chronic phase	published	15	2011	<a href="http://eprints.hta.lbg.ac.at/906/">http://eprints.hta.lbg.ac.at/906/</a>
Cabazitaxel (Jevtana®) for the second-line therapy of patients with hormone-refractory metastatic prostate cancer	published	16	2011	<a href="http://eprints.hta.lbg.ac.at/911/">http://eprints.hta.lbg.ac.at/911/</a>
Dasatinib (Sprycel®) for the first-line therapy of patients with newly diagnosed chronic phase philadelphia chromosme positive chronic myeloid leukemia	published	17	2011	<a href="http://eprints.hta.lbg.ac.at/910/">http://eprints.hta.lbg.ac.at/910/</a>
Eribulin (Halaven®) as third- or late- line mono-therapy for advanced/metastatic breast cancer	published	18	2011	<a href="http://eprints.hta.lbg.ac.at/927/">http://eprints.hta.lbg.ac.at/927/</a>
S-1 (Teysuno) in chemotherapy-naive patients with advanced NSCLC.	published	19	2011	<a href="http://eprints.hta.lbg.ac.at/931/">http://eprints.hta.lbg.ac.at/931/</a>
Abiraterone acetate (Zytiga™) as 2nd-line therapy for the treatment of metastatic castration-resistant prostate cancer after docetaxel therapy	published	20	2011	<a href="http://eprints.hta.lbg.ac.at/938/">http://eprints.hta.lbg.ac.at/938/</a>
Gefitinib (Iressa®) for the 1st-line treatment of non-small cell lung cancer – 1st Update 2011	published	6/ Update 2011	2011	<a href="http://eprints.hta.lbg.ac.at/935/">http://eprints.hta.lbg.ac.at/935/</a>
Rituximab (Rituxan®/MabThera®) for the first- and second-line treatment of chronic lymphocytic leukaemia - 1st Update 2011	published	4/ Update 2011	2011	<a href="http://eprints.hta.lbg.ac.at/937/">http://eprints.hta.lbg.ac.at/937/</a>
Panitumumab (Vectibix®) as 1st line combination therapy for the treatment of WT KRAS metastatic colorectal cancer - 1st Update 2011	published	11/ Update 2011	2011	<a href="http://eprints.hta.lbg.ac.at/936/">http://eprints.hta.lbg.ac.at/936/</a>
Axitinib for 2nd-line metastatic renal cell carcinoma	published	21	2012	<a href="http://eprints.hta.lbg.ac.at/945/">http://eprints.hta.lbg.ac.at/945/</a>
Erlotinib for the 1st -line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR activating mutations	published	22	2012	<a href="http://eprints.hta.lbg.ac.at/941/">http://eprints.hta.lbg.ac.at/941/</a>
Vemurafenib for the 1st –line unresectable stage IIIC or IV melanoma	published	23	2012	<a href="http://eprints.hta.lbg.ac.at/940/">http://eprints.hta.lbg.ac.at/940/</a>
Everolimus for advanced pancreatic neuroendocrine tumours	published	24	2012	<a href="http://eprints.hta.lbg.ac.at/942/">http://eprints.hta.lbg.ac.at/942/</a>
Romidepsin for the treatment of peripheral t-cell lymphoma	published	25	2012	<a href="http://eprints.hta.lbg.ac.at/956/">http://eprints.hta.lbg.ac.at/956/</a>
Brentuximab vedotin for the treatment of Hodgkin Lymphoma and systemic anaplastic large cell lymphoma	published	26	2012	<a href="http://eprints.hta.lbg.ac.at/955/">http://eprints.hta.lbg.ac.at/955/</a>
Bevacizumab in combination with chemotherapy regimens for previously treated HER2-negative metastatic breast cancer	published	27	2012	<a href="http://eprints.hta.lbg.ac.at/952/">http://eprints.hta.lbg.ac.at/952/</a>



Title	Status	No.	Year	Download/Link
Lenalidomide for the treatment of myelodysplastic syndromes	published	28	2012	<a href="http://eprints.hta.lbg.ac.at/954/">http://eprints.hta.lbg.ac.at/954/</a>
Bortezomib for the treatment of multiple myeloma in a transplant setting	published	29	2012	<a href="http://eprints.hta.lbg.ac.at/976/">http://eprints.hta.lbg.ac.at/976/</a>
Ipilimumab for the first-line therapy of advanced/metastatic melanoma	published	30	2012	<a href="http://eprints.hta.lbg.ac.at/970/">http://eprints.hta.lbg.ac.at/970/</a>
Pertuzumab for the first-line therapy of metastatic HER2 positive breast cancer	published	31	2012	<a href="http://eprints.hta.lbg.ac.at/978/">http://eprints.hta.lbg.ac.at/978/</a>
Everolimus for the treatment of breast cancer	published	32	2012	<a href="http://eprints.hta.lbg.ac.at/977/">http://eprints.hta.lbg.ac.at/977/</a>
Lenalidomide for the first-line therapy of multiple myeloma	published	33	2012	<a href="http://eprints.hta.lbg.ac.at/984/">http://eprints.hta.lbg.ac.at/984/</a>
Trametinib for advanced or metastatic BRAF V600E mutation-positive melanoma	published	34	2012	<a href="http://eprints.hta.lbg.ac.at/988/">http://eprints.hta.lbg.ac.at/988/</a>
Crizotinib, PF-01231066 (Xalkori®) for the treatment of anaplastic lymphoma kinase (ALK) positive advanced non-small cell lung cancer (NSCLC).	published	35	2012	<a href="http://eprints.hta.lbg.ac.at/993/">http://eprints.hta.lbg.ac.at/993/</a>
Trastuzumab emtansine (Kadcyla™) for previously treated patients with HER2-positive advanced/metastatic breast cancer	published	36	2013	<a href="http://eprints.hta.lbg.ac.at/998/">http://eprints.hta.lbg.ac.at/998/</a>
Enzalutamide (Xtandi®) for patients with progressive castration-resistant prostate cancer previously treated with docetaxel-based chemotherapy	published	37	2013	<a href="http://eprints.hta.lbg.ac.at/997/">http://eprints.hta.lbg.ac.at/997/</a>
Aflibercept (Zaltrap®) in addition to FOLFIRI for the treatment of metastatic colorectal cancer	published	38	2013	<a href="http://eprints.hta.lbg.ac.at/999/">http://eprints.hta.lbg.ac.at/999/</a>
Pomalidomide (Pomalyst®) in combination with low-dose dexamethasone vs. high-dose dexamethasone in subjects with refractory multiple myeloma or relapsed and refractory multiple myeloma	published	39	2013	<a href="http://eprints.hta.lbg.ac.at/1010/">http://eprints.hta.lbg.ac.at/1010/</a>
Regorafenib (Stivarga®) in pts with metastatic colorectal cancer (CRC) who have progressed after standard therapy	published	40	2013	<a href="http://eprints.hta.lbg.ac.at/1011/">http://eprints.hta.lbg.ac.at/1011/</a>
Afatinib (Gilotrif®) for first-line treatment in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation(s)	published	41	2013	<a href="http://eprints.hta.lbg.ac.at/1020/">http://eprints.hta.lbg.ac.at/1020/</a>
Dabrafenib (Tafinlar®) in previously untreated subjects with BRAF mutation-positive advanced (stage III) or metastatic (stage IV) melanoma	published	42	2013	<a href="http://eprints.hta.lbg.ac.at/1015/">http://eprints.hta.lbg.ac.at/1015/</a>
Nab-Paclitaxel (Abraxane®, Ebetaxel®) as first-line therapy for metastatic adenocarcinoma of the pancreas	published	43	2014	<a href="http://eprints.hta.lbg.ac.at/1023/">http://eprints.hta.lbg.ac.at/1023/</a>
Radium-223 Dichloride (Xofigo®) for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease	published	44	2014	<a href="http://eprints.hta.lbg.ac.at/1024/">http://eprints.hta.lbg.ac.at/1024/</a>
Obinutuzumab afutuzumab (Gazyva®) as first line therapy for chronic lymphocytic leukaemia (CLL)	published	45	2014	<a href="http://eprints.hta.lbg.ac.at/1027/">http://eprints.hta.lbg.ac.at/1027/</a>
Bevacizumab (Avastin®) as maintenance therapy for patients with advanced colorectal carcinoma	published	46	2014	<a href="http://eprints.hta.lbg.ac.at/1034/">http://eprints.hta.lbg.ac.at/1034/</a>
Ibrutinib, PCI-32765 (Imbruvica®) for relapsed or refractory CLL	published	47	2014	<a href="http://eprints.hta.lbg.ac.at/1037/">http://eprints.hta.lbg.ac.at/1037/</a>
Bevacizumab (Avastin®) for platinum-resistant, epithelial ovarian, fallopian tube or primary peritoneal cancer	published	48	2014	<a href="http://eprints.hta.lbg.ac.at/1038/">http://eprints.hta.lbg.ac.at/1038/</a>
Idelalisib (Zydeliq®) in addition to rituximab for the treatment of relapsed chronic lymphocytic leukaemia	published	49	2014	<a href="http://eprints.hta.lbg.ac.at/1044/">http://eprints.hta.lbg.ac.at/1044/</a>
Nivolumab (Opdivo®) as single-agent first-line therapy for unresectable or metastatic melanoma	published	50	2015	<a href="http://eprints.hta.lbg.ac.at/1051/">http://eprints.hta.lbg.ac.at/1051/</a>
Bevacizumab (Avastin®) in combination with chemotherapy as second-line therapy for HER2-negative, locally recurrent or metastatic breast cancer that has progressed after first-line treatment with bevacizumab plus chemotherapy	published	51	2015	<a href="http://eprints.hta.lbg.ac.at/1066/">http://eprints.hta.lbg.ac.at/1066/</a>
Carfilzomib (Kyprolis®) in patients with relapsed multiple myeloma who have received one to three prior lines of therapy	published	52	2015	<a href="http://eprints.hta.lbg.ac.at/1070/">http://eprints.hta.lbg.ac.at/1070/</a>
Nivolumab (Nivolumab BMS®) for the second-line therapy of metastatic squamous non-small cell lung cancer	published	53	2015	<a href="http://eprints.hta.lbg.ac.at/1068/">http://eprints.hta.lbg.ac.at/1068/</a>
Ramucirumab in combination with paclitaxel as second-line treatment for adult patients with advanced gastric or gastro-oesophageal junction carcinoma	published	54	2015	<a href="http://eprints.hta.lbg.ac.at/1069/">http://eprints.hta.lbg.ac.at/1069/</a>
Pembrolizumab (Keytruda®) for the treatment of advanced melanoma	published	55	2015	<a href="http://eprints.hta.lbg.ac.at/1076/">http://eprints.hta.lbg.ac.at/1076/</a>
Bevacizumab (Avastin®) in addition to standard chemotherapy for the first-line treatment of ovarian cancer	published	56	2016	<a href="http://eprints.hta.lbg.ac.at/1082/">http://eprints.hta.lbg.ac.at/1082/</a>
Ofatumumab (Arzerra®) as maintenance therapy in patients with relapsed chronic lymphocytic leukaemia (CLL)	published	57	2016	<a href="http://eprints.hta.lbg.ac.at/1085/">http://eprints.hta.lbg.ac.at/1085/</a>
Pembrolizumab (Keytruda®) in previously treated advanced non-small cell lung cancer (NSCLC)	published	58	2016	<a href="http://eprints.hta.lbg.ac.at/1086/">http://eprints.hta.lbg.ac.at/1086/</a>
Afatinib (Giotrif®) in patients with non-small cell lung cancer (NSCLC) who are refractory to erlotinib/ gefitinib and afatinib monotherapy	published	59	2016	<a href="http://eprints.hta.lbg.ac.at/1089/">http://eprints.hta.lbg.ac.at/1089/</a>
Obinutuzumab (Gazyvaro®) in combination with bendamustine for the treatment of relapsed/refractory follicular lymphoma (FL)	published	60	2016	<a href="http://eprints.hta.lbg.ac.at/1022/">http://eprints.hta.lbg.ac.at/1022/</a>
Atezolizumab (Tecentriq™) for the treatment of locally advanced and metastatic urothelial carcinoma	published	61	2016	<a href="http://eprints.hta.lbg.ac.at/1048/">http://eprints.hta.lbg.ac.at/1048/</a>
Venetoclax (Venclexta™) for the treatment of relapsed or refractory chronic lymphocytic leukaemia (CLL) with chromosome 17p deletion	published	62	2016	<a href="http://eprints.hta.lbg.ac.at/1083/">http://eprints.hta.lbg.ac.at/1083/</a>
Ixazomib (Ninlaro®) in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma (MM)	published	63	2016	<a href="http://eprints.hta.lbg.ac.at/1111/">http://eprints.hta.lbg.ac.at/1111/</a>
Palbociclib (Ibrance®) in combination with fulvestrant for the treatment of hormone-receptor-positive, HER2-negative advanced or metastatic breast cancer	published	64	2017	<a href="http://eprints.hta.lbg.ac.at/1114/">http://eprints.hta.lbg.ac.at/1114/</a>
Ribociclib in combination with letrozole for the first-line therapy of HR-positive, HER2-negative recurrent or metastatic breast cancer	published	65	2017	<a href="http://eprints.hta.lbg.ac.at/1115/">http://eprints.hta.lbg.ac.at/1115/</a>
Neratinib for the treatment of patients with HER2-positive breast cancer after trastuzumab-based adjuvant therapy	published	66	2017	<a href="http://eprints.hta.lbg.ac.at/1116/">http://eprints.hta.lbg.ac.at/1116/</a>
Ipilimumab (Yervoy®) in the adjuvant therapy for high-risk stage III cutaneous melanoma	published	67	2017	<a href="http://eprints.hta.lbg.ac.at/1119/">http://eprints.hta.lbg.ac.at/1119/</a>
Atezolizumab (Tecentriq®) in previously treated non-small cell lung cancer (NSCLC)	published	68	2017	<a href="http://eprints.hta.lbg.ac.at/1120/">http://eprints.hta.lbg.ac.at/1120/</a>
Ceritinib (Zykadia®) as first-line therapy for patients with advanced ALK-positive non-small cell lung cancer	published	69	2017	<a href="http://eprints.hta.lbg.ac.at/1123/">http://eprints.hta.lbg.ac.at/1123/</a>
Pembrolizumab (Keytruda®) as second-line treatment for patients with advanced urothelial carcinoma (UC)	published	70	2017	<a href="http://eprints.hta.lbg.ac.at/1124/">http://eprints.hta.lbg.ac.at/1124/</a>
Olaparib (Lynparza®) in patients with BRCA-mutated metastatic breast cancer	published	71	2017	<a href="http://eprints.hta.lbg.ac.at/1136/">http://eprints.hta.lbg.ac.at/1136/</a>
Abemaciclib (Verzenio®) in combination with fulvestrant for treatment of HR-positive, HER2-negative advanced breast cancer (ABC)	published	72	2017	<a href="http://eprints.hta.lbg.ac.at/1137/">http://eprints.hta.lbg.ac.at/1137/</a>
Regorafenib indicated as monotherapy for the treatment of adult patients with hepatocellular carcinoma who have been previously treated with sorafenib. EUnetHTA report	published	73	2017	<a href="http://eprints.hta.lbg.ac.at/1138/">http://eprints.hta.lbg.ac.at/1138/</a>
Midostaurin with standard chemotherapy in FLT3-Positive Acute Myeloid Leukaemia	published	74	2017	<a href="http://eprints.hta.lbg.ac.at/1140/">http://eprints.hta.lbg.ac.at/1140/</a>
Nivolumab (Opdivo®) for metastatic DNA mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) colorectal cancer (CRC)	published	75	2017	<a href="http://eprints.hta.lbg.ac.at/1144/">http://eprints.hta.lbg.ac.at/1144/</a>
Durvalumab (Imfinzi™) for the treatment of patients with stage III non-small-cell lung cancer after prior chemoradiotherapy	published	76	2017	<a href="http://eprints.hta.lbg.ac.at/1145/">http://eprints.hta.lbg.ac.at/1145/</a>
Alectinib as monotherapy for the first-line treatment of adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC)	published	77	2018	<a href="http://eprints.hta.lbg.ac.at/1152/">http://eprints.hta.lbg.ac.at/1152/</a>
Abemaciclib (Verzenio®) in combination with a nonsteroidal aromatase inhibitor (NSAI) as initial therapy for advanced breast cancer (ABC)	published	78	2018	<a href="http://eprints.hta.lbg.ac.at/1154/">http://eprints.hta.lbg.ac.at/1154/</a>

Title	Status	No.	Year	Download/Link
Rituximab (MabThera®) after autologous stem-cell transplantation (ASCT) in mantle cell lymphoma (MCL)	published	79	2018	<a href="http://eprints.hta.lbg.ac.at/1155/">http://eprints.hta.lbg.ac.at/1155/</a>
Osimertinib (Tagrisso®) for the initial treatment of EGFR-mutated advanced non-small-cell lung cancer (NSCLC)	published	80	2018	<a href="http://eprints.hta.lbg.ac.at/1160/">http://eprints.hta.lbg.ac.at/1160/</a>
Daratumumab (Darzalex®) in combination with bortezomib, melphalan and prednisone for untreated myeloma	published	81	2018	<a href="http://eprints.hta.lbg.ac.at/1161/">http://eprints.hta.lbg.ac.at/1161/</a>
Nivolumab (Opdivo®) in combination with ipilimumab (Yervoy®) for the first-line treatment of patients with advanced RCC	published	82	2018	<a href="http://eprints.hta.lbg.ac.at/1175/">http://eprints.hta.lbg.ac.at/1175/</a>
Pembrolizumab (Keytruda®) in combination with chemotherapy for the treatment of metastatic non-small-cell lung cancer (NSCLC)	published	83	2018	<a href="http://eprints.hta.lbg.ac.at/1176/">http://eprints.hta.lbg.ac.at/1176/</a>
Enzalutamide (Xtandi®) in patients with nonmetastatic, castration-resistant prostate cancer (CRPC)	published	84	2018	<a href="http://eprints.hta.lbg.ac.at/1184/">http://eprints.hta.lbg.ac.at/1184/</a>
Ibrutinib (Imbruvica®) in combination with rituximab for the treatment of Waldenström's macroglobulinemia	published	85	2018	<a href="http://eprints.hta.lbg.ac.at/1185/">http://eprints.hta.lbg.ac.at/1185/</a>
Olaparib (Lynparza®) für die Erstlinien-Erhaltungstherapie von Patientinnen mit neu diagnostiziertem, fortgeschrittenem Ovarialkarzinom	published	86	2019	<a href="http://eprints.hta.lbg.ac.at/1192/">http://eprints.hta.lbg.ac.at/1192/</a>
Atezolizumab (Tecentriq®) und Nab-Paclitaxel (Abraxane®) für die Behandlung von Patientinnen mit fortgeschrittenem, triple-negativem Mammakarzinom (aTNBC)	published	87	2019	<a href="http://eprints.hta.lbg.ac.at/1193/">http://eprints.hta.lbg.ac.at/1193/</a>
Darolutamide für die Behandlung von Patienten mit nichtmetastatischem, kastrationsresistentem Prostatakarzinom	published	88	2019	<a href="http://eprints.hta.lbg.ac.at/1199/">http://eprints.hta.lbg.ac.at/1199/</a>
Brentuximab vedotin (Adcetris®) in combination with chemotherapy for CD30-positive peripheral T-cell lymphoma (PTCLs)	published	89	2019	<a href="http://eprints.hta.lbg.ac.at/1210/">http://eprints.hta.lbg.ac.at/1210/</a>
Enzalutamide (Xtandi®) in addition to standard first-line therapy in men with metastatic hormone-sensitive prostate cancer (mHSPC)	published	90	2019	<a href="http://eprints.hta.lbg.ac.at/1216/">http://eprints.hta.lbg.ac.at/1216/</a>
Pembrolizumab (Keytruda®) as first-line therapy for PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (NSCLC)	published	91	2019	<a href="http://eprints.hta.lbg.ac.at/1219/">http://eprints.hta.lbg.ac.at/1219/</a>
<b>Decision Support Documents: Oncology Fact Sheets</b>				
Venetoclax (Venclyxto®) and obinutuzumab in patients with chronic lymphocytic leukaemia (CLL) and coexisting conditions	published	1	2020	<a href="http://eprints.aihta.at/1229/">http://eprints.aihta.at/1229/</a>
Darolutamide (Nubeqa®) in nonmetastatic, castration-resistant prostate cancer (nmCRPC)	published	2	2020	<a href="http://eprints.aihta.at/1230/">http://eprints.aihta.at/1230/</a>
Rituximab (MabThera®) for the treatment of paediatric patients with previously untreated advanced stage CD20 positive DLBCL, BL, BAL, or BLL	published	3	2020	<a href="http://eprints.aihta.at/1231/">http://eprints.aihta.at/1231/</a>
Brigatinib (Alunbrig®) in ALK-positive non-small-cell lung cancer (NSCLC)	published	4	2020	<a href="http://eprints.aihta.at/1232/">http://eprints.aihta.at/1232/</a>
Brentuximab vedotin (Adcetris®) with chemotherapy for CD30-positive peripheral T-cell lymphoma (PTCL)	published	5	2020	<a href="http://eprints.aihta.at/1235/">http://eprints.aihta.at/1235/</a>
Isatuximab (Sarclisa®) plus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (MM)	published	6	2020	<a href="http://eprints.aihta.at/1236/">http://eprints.aihta.at/1236/</a>
Encorafenib (Braftovi®) in combination with cetuximab for the treatment of adult patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation	published	7	2020	<a href="http://eprints.aihta.at/1240/">http://eprints.aihta.at/1240/</a>
Cabazitaxel Accord for the treatment of patients with metastatic castration resistant prostate cancer (mCRPC) previously treated with a docetaxel containing regimen	published	8	2020	<a href="http://eprints.aihta.at/1241/">http://eprints.aihta.at/1241/</a>
Daratumumab (Darzalex®) in a new pharmaceutical form associated with a new strength and a new route of administration for the treatment of multiple myeloma	published	9	2020	<a href="http://eprints.aihta.at/1242/">http://eprints.aihta.at/1242/</a>
Glasdegib (Daurismo®) with low-dose cytarabine (LDAC) in patients with newly diagnosed acute myeloid leukaemia (AML)	published	10	2020	<a href="http://eprints.aihta.at/1243/">http://eprints.aihta.at/1243/</a>
Maintenance olaparib (Lynparza®) for the treatment of patients with germline BRCA-mutated metastatic pancreatic cancer	published	11	2020	<a href="http://eprints.aihta.at/1246/">http://eprints.aihta.at/1246/</a>
Alpelisib (Piqray®) plus fulvestrant for PIK3CA-mutated, hormone receptor-positive advanced breast cancer	published	12	2020	<a href="http://eprints.aihta.at/1247/">http://eprints.aihta.at/1247/</a>
Entrectinib (Rozlytrek®) for the treatment of patients whose solid tumours have a NTRK gene fusion, or patients with ROS1-positive advanced NSCLC	published	13	2020	<a href="http://eprints.aihta.at/1248/">http://eprints.aihta.at/1248/</a>
Carmustine (Carmustine Obvius®) as conditioning treatment before transplantation in patients with Hodgkin's lymphoma (HL) and non-Hodgkin's lymphomas (NHL)	published	14	2020	<a href="https://eprints.aihta.at/1261/">https://eprints.aihta.at/1261/</a>
Acalabrutinib (Calquence®) for the treatment of chronic lymphocytic leukaemia (CLL)	published	15	2020	<a href="https://eprints.aihta.at/1263/">https://eprints.aihta.at/1263/</a>
Avapritinib (Ayyakyt®) for the treatment of gastrointestinal stromal tumours (GIST)	published	16	2020	<a href="https://eprints.aihta.at/1264/">https://eprints.aihta.at/1264/</a>
Belantamab mafodotin (Blenrep®) as monotherapy for the treatment of relapsed or refractory multiple myeloma (MM)	published	17	2020	<a href="https://eprints.aihta.at/1265/">https://eprints.aihta.at/1265/</a>
Durvalumab (Imfinzi®) in combination with etoposide and either carboplatin or cisplatin for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC)	published	18	2020	<a href="https://eprints.aihta.at/1266/">https://eprints.aihta.at/1266/</a>
Ibrutinib (Imbruvica®) as a single agent or in combination with rituximab or obinutuzumab for the treatment of previously untreated chronic lymphocytic leukaemia (CLL)	published	19	2020	<a href="https://eprints.aihta.at/1267/">https://eprints.aihta.at/1267/</a>
Atezolizumab (Tecentriq®) plus bevacizumab for the treatment of advanced or unresectable hepatocellular carcinoma (HCC)	published	20	2020	<a href="https://eprints.aihta.at/1270/">https://eprints.aihta.at/1270/</a>
Nivolumab (Opdivo®) plus ipilimumab (Yervoy®) and chemotherapy as first-line treatment for metastatic non-small cell lung cancer (NSCLC)	published	21	2020	<a href="https://eprints.aihta.at/1271/">https://eprints.aihta.at/1271/</a>
Niraparib (Zejula®) in patients with newly diagnosed advanced ovarian cancer	published	22	2020	<a href="https://eprints.aihta.at/1272/">https://eprints.aihta.at/1272/</a>
Olaparib (Lynparza®) for metastatic castration-resistant prostate cancer (mCRPC)	published	23	2020	<a href="https://eprints.aihta.at/1273/">https://eprints.aihta.at/1273/</a>
Olaparib (Lynparza®) plus bevacizumab as first-line maintenance treatment in patients with ovarian cancer	published	24	2020	<a href="https://eprints.aihta.at/1274/">https://eprints.aihta.at/1274/</a>
Blinatumomab (Blincyto®) for the treatment of patients with Philadelphia chromosome positive B-precursor acute lymphoblastic leukaemia (ALL)	published	25	2020	<a href="https://eprints.aihta.at/1276/">https://eprints.aihta.at/1276/</a>
Nivolumab (Opdivo®) as monotherapy for the treatment of unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma (OESCC)	published	26	2020	<a href="https://eprints.aihta.at/1277/">https://eprints.aihta.at/1277/</a>
Autologous anti-CD19-transduced CD3+ cells (Tecartus®) for the treatment of relapsed or refractory mantle cell lymphoma (MCL)	published	27	2020	<a href="https://eprints.aihta.at/1278/">https://eprints.aihta.at/1278/</a>
Tagraxofusp (Elzonris®) in blastic plasmacytoid dendritic-cell neoplasm (BPDCN)	published	28	2020	<a href="https://eprints.aihta.at/1284/">https://eprints.aihta.at/1284/</a>
Carfilzomib (Kyprolis®) with daratumumab and dexamethasone for the treatment of adult patients with multiple myeloma (MM)	published	29	2020	<a href="https://eprints.aihta.at/1285/">https://eprints.aihta.at/1285/</a>
A fixed-dose combination of pertuzumab, trastuzumab and hyaluronidase-zzxf (Phesgo™) for the treatment of early and metastatic breast cancer	published	30	2020	<a href="https://eprints.aihta.at/1286/">https://eprints.aihta.at/1286/</a>
Avelumab (Bavencio®) as monotherapy for the first-line maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma	published	31	2020	<a href="https://eprints.aihta.at/1287/">https://eprints.aihta.at/1287/</a>
Trastuzumab deruxtecan (Enhertu®) in patients with previously treated HER2-positive breast cancer	published	32	2021	<a href="https://eprints.aihta.at/1288/">https://eprints.aihta.at/1288/</a>
Fedratinib (Inrebic®) for the treatment of primary and secondary myelofibrosis	published	33	2020	<a href="https://eprints.aihta.at/1289/">https://eprints.aihta.at/1289/</a>
Pembrolizumab (Keytruda®) as monotherapy for the first-line treatment of MSI H or dMMR colorectal cancer	published	34	2021	<a href="https://eprints.aihta.at/1290/">https://eprints.aihta.at/1290/</a>
Moxetumomab pasudotox (Lumoxiti®) for the treatment of patients with relapsed or refractory hairy cell leukaemia (HCL)	published	35	2021	<a href="https://eprints.aihta.at/1291/">https://eprints.aihta.at/1291/</a>
Selpercatinib (Retsevmo®) for the treatment of RET-fusion positive NSCLC, RET-fusion positive thyroid cancer and RET-mutant medullary-thyroid cancer	published	36	2021	<a href="https://eprints.aihta.at/1292/">https://eprints.aihta.at/1292/</a>
Tucatinib (Tukysa®) with trastuzumab and capecitabine for the treatment of HER2-positive locally advanced or metastatic breast cancer	published	37	2021	<a href="https://eprints.aihta.at/1293/">https://eprints.aihta.at/1293/</a>
Pembrolizumab (Keytruda®) is indicated for the treatment of adult and paediatric patients with relapsed or refractory classical Hodgkin lymphoma (cHL)	published	38	2021	<a href="https://eprints.aihta.at/1296/">https://eprints.aihta.at/1296/</a>
Selinexor (Nexpovio®) in combination with dexamethasone for the treatment of relapsed and refractory multiple myeloma (MM)	published	39	2021	<a href="https://eprints.aihta.at/1297/">https://eprints.aihta.at/1297/</a>
Pemigatinib (Pemazyre®) for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement	published	40	2021	<a href="https://eprints.aihta.at/1298/">https://eprints.aihta.at/1298/</a>

Title	Status	No.	Year	Download/Link
Dostarlimab (Jemperli®) for the treatment of patients with recurrent or advanced mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) endometrial cancer (EC)	published	41	2021	<a href="https://eprints.aihta.at/1299/">https://eprints.aihta.at/1299/</a>
Nivolumab (Opdivo®) in combination with cabozantinib (Cabometyx®) for the first-line treatment of patients with advanced renal cell carcinoma (RCC)	published	42	2021	<a href="https://eprints.aihta.at/1300/">https://eprints.aihta.at/1300/</a>
Isatuximab (Sarclisa®) in combination with carfilzomib and dexamethasone for the treatment of patients with multiple myeloma (MM)	published	43	2021	<a href="https://eprints.aihta.at/1301/">https://eprints.aihta.at/1301/</a>
Duvelisib (Copiktra®) for the treatment of patients with relapsed or refractory chronic lymphocytic leukaemia (CLL) and refractory follicular lymphoma (FL)	published	44	2021	<a href="https://eprints.aihta.at/1304/">https://eprints.aihta.at/1304/</a>
Atezolizumab (Tecentriq®) as monotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC)	published	45	2021	<a href="https://eprints.aihta.at/1305/">https://eprints.aihta.at/1305/</a>
Enzalutamide (Xtandi®) for the treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (ADT)	published	46	2021	<a href="https://eprints.aihta.at/1306/">https://eprints.aihta.at/1306/</a>
Azacitidine (Onureg®) for the maintenance treatment of patients with acute myeloid leukaemia (AML)	published	47	2021	<a href="https://eprints.aihta.at/1309/">https://eprints.aihta.at/1309/</a>
Osimertinib (Tagrisso®) as monotherapy for the adjuvant treatment after complete tumour resection in adult patients with stage IB-IIIA non-small cell lung cancer (NSCLC)	published	48	2021	<a href="https://eprints.aihta.at/1310/">https://eprints.aihta.at/1310/</a>
Venetoclax (Venclyxto®) in combination with a hypomethylating agent for the treatment of patients with newly diagnosed acute myeloid leukaemia (AML)	published	49	2021	<a href="https://eprints.aihta.at/1311/">https://eprints.aihta.at/1311/</a>
Nivolumab (Opdivo®) in combination with ipilimumab for the first-line treatment of patients with unresectable malignant pleural mesothelioma	published	50	2021	<a href="https://eprints.aihta.at/1312/">https://eprints.aihta.at/1312/</a>
Nivolumab (Opdivo®) in combination with ipilimumab (Yervoy®) for the treatment of patients with mismatch repair deficient (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer	published	51	2021	<a href="https://eprints.aihta.at/1315/">https://eprints.aihta.at/1315/</a>
Cemiplimab (Libtayo®) as monotherapy for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC)	published	52	2021	<a href="https://eprints.aihta.at/1316/">https://eprints.aihta.at/1316/</a>
Cemiplimab (Libtayo®) as monotherapy for the treatment of locally advanced or metastatic basal cell carcinoma (laBCC or mBCC)	published	53	2021	<a href="https://eprints.aihta.at/1317/">https://eprints.aihta.at/1317/</a>
Pembrolizumab (Keytruda®) in combination with platinum and fluoropyrimidine based chemotherapy for the treatment of locally advanced unresectable or metastatic carcinoma of the oesophagus	published	54	2021	<a href="https://eprints.aihta.at/1318/">https://eprints.aihta.at/1318/</a>
Daratumumab (Darzalex®) in combination with pomalidomide and dexamethasone for the treatment of multiple myeloma (MM)	published	55	2021	<a href="https://eprints.aihta.at/1319/">https://eprints.aihta.at/1319/</a>
Daratumumab (Darzalex®) in combination with cyclophosphamide, bortezomib and dexamethasone for the treatment of newly diagnosed systemic light chain (AL) amyloidosis	published	56	2021	<a href="https://eprints.aihta.at/1320/">https://eprints.aihta.at/1320/</a>
Idecabtagene vicleuceel (Abecma®) for the treatment of patients with relapsed and refractory multiple myeloma (MM)	published	57	2021	<a href="https://eprints.aihta.at/1330/">https://eprints.aihta.at/1330/</a>
Tafasitamab (Minjovi®; Monjuvi®) for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)	published	58	2021	<a href="https://eprints.aihta.at/1331/">https://eprints.aihta.at/1331/</a>
Adjuvant nivolumab (Opdivo®) as monotherapy for the treatment of patients with oesophageal (OC) or gastro-oesophageal junction cancer (GEJC)	published	59	2021	<a href="https://eprints.aihta.at/1332/">https://eprints.aihta.at/1332/</a>
Zanubrutinib (Brukinsa®) as monotherapy for the treatment of patients with waldenström's macroglobulinaemia (WM)	published	60	2021	<a href="https://eprints.aihta.at/1336/">https://eprints.aihta.at/1336/</a>
Pralsetinib (Gavreto®) as monotherapy for the treatment of patients with rearranged during transfection (RET) fusion-positive advanced non-small cell lung cancer (NSCLC)	published	61	2021	<a href="https://eprints.aihta.at/1337/">https://eprints.aihta.at/1337/</a>
Ripretinib (Qinlock®) for the treatment of patients with advanced gastrointestinal stromal tumour (GIST)	published	62	2021	<a href="https://eprints.aihta.at/1338/">https://eprints.aihta.at/1338/</a>
Nivolumab (Opdivo®) in combination with fluoropyrimidine- and platinum-based combination chemotherapy for the treatment of patients with HER2?negative advanced or metastatic gastric, gastro?oesophageal junction or oesophageal adenocarcinoma	published	63	2021	<a href="https://eprints.aihta.at/1339/">https://eprints.aihta.at/1339/</a>
Pembrolizumab (Keytruda®) in combination with chemotherapy for the treatment of locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC)	published	64	2021	<a href="https://eprints.aihta.at/1340/">https://eprints.aihta.at/1340/</a>
Pembrolizumab (Keytruda) in combination with Lenvatinib (Kisplyx) for the firstline treatment of advanced renal cell carcinoma (RCC)	published	67	2021	<a href="https://eprints.aihta.at/1343/">https://eprints.aihta.at/1343/</a>
Pembrolizumab (Keytruda) in combination with Lenvatinib (Kisplyx) for the treatment of advanced or recurrent endometrial carcinoma (EC)	published	68	2021	<a href="https://eprints.aihta.at/1344/">https://eprints.aihta.at/1344/</a>
Amivantamab (Rybrevant) as monotherapy for the treatment of patients with advanced non-small cell lung cancer (NSCLC)	published	69	2021	<a href="https://eprints.aihta.at/1345/">https://eprints.aihta.at/1345/</a>
Sacituzumab govitecan (Trodelvy) as monotherapy for the treatment of patients with unresectable or metastatic triple-negative breast cancer (mTNBC)	published	70	2021	<a href="https://eprints.aihta.at/1346/">https://eprints.aihta.at/1346/</a>
Sotorasib (Lumykras®): Sotorasib (Lumykras®) as monotherapy for the treatment of advanced NSCLC with KRAS G12C mutation	published	71	2021	<a href="https://eprints.aihta.at/1347/">https://eprints.aihta.at/1347/</a>
Enfortumab vedotin (Padcev®) as monotherapy for the treatment of patients with locally advanced or metastatic urothelial cancer	published	72	2022	<a href="https://eprints.aihta.at/1353/">https://eprints.aihta.at/1353/</a>
Tepotinib (Tepmetko®) as monotherapy for the treatment of patients with advanced non-small cell lung cancer (NSCLC)	published	73	2022	<a href="https://eprints.aihta.at/1354/">https://eprints.aihta.at/1354/</a>
Pembrolizumab (Keytruda®) as monotherapy for the adjuvant treatment of renal cell carcinoma (RCC)	published	74	2022	<a href="https://eprints.aihta.at/1355/">https://eprints.aihta.at/1355/</a>
Lorlatinib (Lorviqua®) as monotherapy for the treatment of anaplastic lymphoma kinase (ALK) positive advanced non-small cell lung cancer (NSCLC)	published	75	2022	<a href="https://eprints.aihta.at/1356/">https://eprints.aihta.at/1356/</a>
Tegafur/gimeracil/oteracil (Teysono®) for the treatment of metastatic colorectal cancer	published	76	2022	<a href="https://eprints.aihta.at/1357/">https://eprints.aihta.at/1357/</a>
Lisocabtagene maraleuceel (Breyanzi) for the treatment of relapsed or refractory DLBCL	published	77	2022	<a href="https://eprints.aihta.at/1359/">https://eprints.aihta.at/1359/</a>
Avapritinib (Ayyvakt®) for the treatment of advanced systemic mastocytosis (AdvSM)	published	78	2022	<a href="https://eprints.aihta.at/1360/">https://eprints.aihta.at/1360/</a>
Tebentafusp (Kimmtrak®) bei Uveal melanoma	published	79	2022	<a href="https://eprints.aihta.at/1361/">https://eprints.aihta.at/1361/</a>
Relugolix (Orgovyx®) bei Prostate Cancer	published	80	2022	<a href="https://eprints.aihta.at/1362/">https://eprints.aihta.at/1362/</a>
Nivolumab (Opdivo®) bei MIUC	published	81	2022	<a href="https://eprints.aihta.at/1363/">https://eprints.aihta.at/1363/</a>
Ipilimumab (Yervoy®) + Nivolumab (Opdivo®) bei OSCC	published	82	2022	<a href="https://eprints.aihta.at/1364/">https://eprints.aihta.at/1364/</a>
Nivolumab (Opdivo®) + chemotherapy bei OSCC	published	83	2022	<a href="https://eprints.aihta.at/1365/">https://eprints.aihta.at/1365/</a>
Abemaciclib (Verzenios®) bei early breast cancer	published	84	2022	<a href="https://eprints.aihta.at/1366/">https://eprints.aihta.at/1366/</a>
Enfortumab vedotin (Padcev®) as monotherapy for the treatment of patients with locally advanced or metastatic urothelial cancer	published	85	2022	<a href="https://eprints.aihta.at/1367/">https://eprints.aihta.at/1367/</a>
Ciltacabtagene autoleuceel (Carvykti®) for the treatment of multiple myeloma (MM)	published	86	2022	<a href="https://eprints.aihta.at/1371/">https://eprints.aihta.at/1371/</a>
Cabozantinib (Cabometyx®) as monotherapy for the treatment of thyroid carcinoma (DTC)	published	87	2022	<a href="https://eprints.aihta.at/1372/">https://eprints.aihta.at/1372/</a>
Tisagenlecleuceel (Kymriah®) for the treatment of follicular lymphoma (FL) after two or more lines of systemic therapy	published	88	2022	<a href="https://eprints.aihta.at/1373/">https://eprints.aihta.at/1373/</a>
Polatuzumab vedotin (Polivy®) in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for the treatment of B-cell lymphoma (DLBCL)	published	89	2022	<a href="https://eprints.aihta.at/1374/">https://eprints.aihta.at/1374/</a>
Pembrolizumab (Keytruda®) as monotherapy in adults with colorectal cancer	published	90	2022	<a href="https://eprints.aihta.at/1375/">https://eprints.aihta.at/1375/</a>
Pembrolizumab (Keytruda®) in combination with chemotherapy with or without bevacizumab for cervical cancer	published	91	2022	<a href="https://eprints.aihta.at/1376/">https://eprints.aihta.at/1376/</a>
Mosunetuzumab (Lunsumio®) Follicular lymphoma	published	92	2022	<a href="https://eprints.aihta.at/1377/">https://eprints.aihta.at/1377/</a>
Capmatinib (Tabrecta®) NSCLC	published	93	2022	<a href="https://eprints.aihta.at/1378/">https://eprints.aihta.at/1378/</a>
Pembrolizumab (Keytruda®) TNBC	published	94	2022	<a href="https://eprints.aihta.at/1379/">https://eprints.aihta.at/1379/</a>
Selpercatinib (Retsevmo®) NSCLC	published	95	2022	<a href="https://eprints.aihta.at/1380/">https://eprints.aihta.at/1380/</a>

Title	Status	No.	Year	Download/Link
Atezolizumab (Tecentriq®) NSCLC	published	96	2022	<a href="https://eprints.aihta.at/1381/">https://eprints.aihta.at/1381/</a>
Axicabtagene ciloleuce (Yescarta®) Follicular lymphoma	published	97	2022	<a href="https://eprints.aihta.at/1382/">https://eprints.aihta.at/1382/</a>
Selinexor (Nexpovio®) in combination with bortezomib and dexamethasone for the treatment of multiple myeloma (MM)	published	98	2022	<a href="https://eprints.aihta.at/1384/">https://eprints.aihta.at/1384/</a>
Pembrolizumab (Keytruda®) as monotherapy for the adjuvant treatment of adults and adolescents aged 12 years and older with stage IIB, IIC or III melanoma who have undergone complete resection	published	99	2022	<a href="https://eprints.aihta.at/1385/">https://eprints.aihta.at/1385/</a>
Melphalan flufenamide (Pepaxti®) with dexamethasone for the treatment of multiple myeloma (MM)	published	100	2022	<a href="https://eprints.aihta.at/1395/">https://eprints.aihta.at/1395/</a>
Asciminib (Scemblix®) for the treatment of Philadelphia chromosome?positive (Ph+) chronic myeloid leukaemia (CML) in chronic phase (CP)	published	101	2022	<a href="https://eprints.aihta.at/1396/">https://eprints.aihta.at/1396/</a>
Trastuzumab deruxtecan (Enhertu®) as monotherapy for the treatment of unresectable or metastatic HER2 positive breast cancer	published	102	2022	<a href="https://eprints.aihta.at/1397/">https://eprints.aihta.at/1397/</a>
Ibrutinib (Imbruvica®) in combination with venetoclax for the treatment of previously untreated chronic lymphocytic leukaemia (CLL)	published	103	2022	<a href="https://eprints.aihta.at/1398/">https://eprints.aihta.at/1398/</a>
Olaparib (Lynparza®) as monotherapy or in combination with endocrine therapy for the adjuvant treatment of patients with germline BRCA1/2-mutations who have HER2-negative, high risk early breast cancer	published	104	2022	<a href="https://eprints.aihta.at/1399/">https://eprints.aihta.at/1399/</a>
Relatimab/nivolumab (Opdualag®) for the first line treatment of advanced melanoma in adults and adolescents 12 years of age and older with tumour cell PD-L1 expression < 1%	published	105	2022	<a href="https://eprints.aihta.at/1403/">https://eprints.aihta.at/1403/</a>
Autologous anti-CD19-transduced CD3+ cells (Tecartus®) for the treatment of adult patients 26 years of age and above with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL)	published	106	2022	<a href="https://eprints.aihta.at/1404/">https://eprints.aihta.at/1404/</a>
Teclistamab (Tecvayli®) as monotherapy for the treatment of patients with relapsed and refractory multiple myeloma (MM) who have received at least three prior therapies	published	107	2022	<a href="https://eprints.aihta.at/1405/">https://eprints.aihta.at/1405/</a>
Selpercatinib (Retsevmo®) as monotherapy for the treatment of adults and adolescents 12 years and older with advanced RET mutant medullary thyroid cancer (MTC)	published	108	2022	<a href="https://eprints.aihta.at/1406/">https://eprints.aihta.at/1406/</a>
Loncastuximab tesirine (Zynlonta®) as monotherapy for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)	published	109	2022	<a href="https://eprints.aihta.at/1409/">https://eprints.aihta.at/1409/</a>
Zanubrutinib (Brukinsa®) as monotherapy for the treatment of marginal zone lymphoma (MZL)	published	110	2022	<a href="https://eprints.aihta.at/1410/">https://eprints.aihta.at/1410/</a>
Axicabtagene ciloleuce (Yescarta®) for the treatment of patients with diffuse large B cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)	published	111	2022	<a href="https://eprints.aihta.at/1411/">https://eprints.aihta.at/1411/</a>
Zanubrutinib (Brukinsa®) as monotherapy for the treatment of adult patients with chronic lymphocytic leukaemia (CLL)	published	112	2022	<a href="https://eprints.aihta.at/1412/">https://eprints.aihta.at/1412/</a>
Cemiplimab (Libtayo®) as monotherapy for the treatment of recurrent or metastatic cervical cancer	published	113	2022	<a href="https://eprints.aihta.at/1413/">https://eprints.aihta.at/1413/</a>
Lutetium (177Lu) vipivotide tetraxetan (Pluvicto®) in combination with androgen deprivation therapy (ADT) with or without androgen receptor (AR) pathway inhibition for the treatment of metastatic castration-resistant prostate cancer (mCRPC)	published	114	2022	<a href="https://eprints.aihta.at/1414/">https://eprints.aihta.at/1414/</a>
<b>Other Reports/ Projects</b>				
Annual Report 2006. German version.	published		2007	<a href="http://eprints.hta.lbg.ac.at/781/">http://eprints.hta.lbg.ac.at/781/</a>
Annual Report 2006. English version.	published		2007	<a href="http://eprints.hta.lbg.ac.at/786/">http://eprints.hta.lbg.ac.at/786/</a>
Annual Report 2007. German version.	published		2008	<a href="http://eprints.hta.lbg.ac.at/782/">http://eprints.hta.lbg.ac.at/782/</a>
Annual Report 2007. English version.	published		2008	<a href="http://eprints.hta.lbg.ac.at/785/">http://eprints.hta.lbg.ac.at/785/</a>
Annual Report 2008. German version.	published		2009	<a href="http://eprints.hta.lbg.ac.at/819/">http://eprints.hta.lbg.ac.at/819/</a>
Annual Report 2008. English version.	published		2009	<a href="http://eprints.hta.lbg.ac.at/821/">http://eprints.hta.lbg.ac.at/821/</a>
Annual Report 2009. German version.	published		2010	<a href="http://eprints.hta.lbg.ac.at/871/">http://eprints.hta.lbg.ac.at/871/</a>
Annual Report 2009. English version.	published		2010	<a href="http://eprints.hta.lbg.ac.at/872/">http://eprints.hta.lbg.ac.at/872/</a>
Annual Report 2010. German version.	published		2011	<a href="http://eprints.hta.lbg.ac.at/904/">http://eprints.hta.lbg.ac.at/904/</a>
Annual Report 2010. English version.	published		2011	<a href="http://eprints.hta.lbg.ac.at/909/">http://eprints.hta.lbg.ac.at/909/</a>
Annual Report 2011. German version.	published		2012	<a href="http://eprints.hta.lbg.ac.at/943/">http://eprints.hta.lbg.ac.at/943/</a>
Annual Report 2011. English version.	published		2012	<a href="http://eprints.hta.lbg.ac.at/944/">http://eprints.hta.lbg.ac.at/944/</a>
"Institut für Health Technology Assessment" unter Mitfinanzierung der Ludwig Boltzmann Gesellschaft 2013-2020	finished		2010	not published
"Institute for Health Technology Assessment" with Co-financing of the Ludwig Boltzmann Gesellschaft 2013 bis 2020	finished		2011	not published
Annual Report 2012. German/English	published		2013	<a href="http://eprints.hta.lbg.ac.at/991/">http://eprints.hta.lbg.ac.at/991/</a>
Annual Report 2013. German/English	published		2014	<a href="http://eprints.hta.lbg.ac.at/1022/">http://eprints.hta.lbg.ac.at/1022/</a>
Annual Report 2014. German/English	published		2015	<a href="http://eprints.hta.lbg.ac.at/1048/">http://eprints.hta.lbg.ac.at/1048/</a>
Annual Report 2015. German/English	published		2016	<a href="http://eprints.hta.lbg.ac.at/1083/">http://eprints.hta.lbg.ac.at/1083/</a>
Annual Report 2016. German/English	published		2017	<a href="http://eprints.hta.lbg.ac.at/1150/">http://eprints.hta.lbg.ac.at/1150/</a>
Annual Report 2017. German/English	published		2018	<a href="http://eprints.hta.lbg.ac.at/1151/">http://eprints.hta.lbg.ac.at/1151/</a>
Annual Report 2018. German/English	published		2019	<a href="http://eprints.hta.lbg.ac.at/1187/">http://eprints.hta.lbg.ac.at/1187/</a>
Annual Report 2019. German/English	published		2020	<a href="http://eprints.hta.lbg.ac.at/1226/">http://eprints.hta.lbg.ac.at/1226/</a>
Annual Report 2020. German/English	published		2021	<a href="https://eprints.aihta.at/1294/">https://eprints.aihta.at/1294/</a>
Annual Report 2021. German/English	published		2022	<a href="https://eprints.aihta.at/1358/">https://eprints.aihta.at/1358/</a>
EUnethTA (European network for Health Technology Assessment) Joint Action 1 - Lead Partner Work package 7B - New Technologies	ongoing		2006-2008, 2009, 2010-2013	<a href="http://www.eunetha.eu/">www.eunetha.eu/</a>
EUnethTA (European network for Health Technology Assessment) Joint Action 2 - Colead Partner Work package 5 - Collaboration	ongoing		2012-2015	<a href="http://www.eunetha.eu/">www.eunetha.eu/</a>
AdHopHTA	ongoing		2012-2015	<a href="http://www.adhophta.eu/">http://www.adhophta.eu/</a>
HSO Priorisation No. 18	published		2014	<a href="http://eprints.hta.lbg.ac.at/1026/">http://eprints.hta.lbg.ac.at/1026/</a>
HSO Priorisation No. 19	published		2014	<a href="http://eprints.hta.lbg.ac.at/1033/">http://eprints.hta.lbg.ac.at/1033/</a>
HSO Priorisation No. 20	published		2014	<a href="http://eprints.hta.lbg.ac.at/1040/">http://eprints.hta.lbg.ac.at/1040/</a>
HSO Priorisation No. 21	published		2015	<a href="http://eprints.hta.lbg.ac.at/1046/">http://eprints.hta.lbg.ac.at/1046/</a>

Title	Status	No.	Year	Download/Link
HSO Priorisation No. 22	published		2015	<a href="http://eprints.hta.lbg.ac.at/1052/">http://eprints.hta.lbg.ac.at/1052/</a>
HSO Priorisation No. 23	published		2015	<a href="http://eprints.hta.lbg.ac.at/1065/">http://eprints.hta.lbg.ac.at/1065/</a>
HSO Priorisation No. 24	published		2015	<a href="http://eprints.hta.lbg.ac.at/1074/">http://eprints.hta.lbg.ac.at/1074/</a>
HSO Priorisation No. 25	published		2016	<a href="http://eprints.hta.lbg.ac.at/1079/">http://eprints.hta.lbg.ac.at/1079/</a>
HSO Priorisation No. 26	published		2016	<a href="http://eprints.hta.lbg.ac.at/1087/">http://eprints.hta.lbg.ac.at/1087/</a>
HSO Priorisation No. 27	published		2016	<a href="http://eprints.hta.lbg.ac.at/1099/">http://eprints.hta.lbg.ac.at/1099/</a>
HSO Priorisation No. 28	published		2016	<a href="http://eprints.hta.lbg.ac.at/1106/">http://eprints.hta.lbg.ac.at/1106/</a>
HSO Priorisation No. 29	published		2017	<a href="http://eprints.hta.lbg.ac.at/1113/">http://eprints.hta.lbg.ac.at/1113/</a>
HSO Priorisation No. 30	published		2017	<a href="http://eprints.hta.lbg.ac.at/1117/">http://eprints.hta.lbg.ac.at/1117/</a>
HSO Priorisation No. 31	published		2017	<a href="http://eprints.hta.lbg.ac.at/1121/">http://eprints.hta.lbg.ac.at/1121/</a>
HSO Priorisation No. 32	published		2017	<a href="http://eprints.hta.lbg.ac.at/1133/">http://eprints.hta.lbg.ac.at/1133/</a>
HSO Priorisation No. 33	published		2018	<a href="http://eprints.hta.lbg.ac.at/1135/">http://eprints.hta.lbg.ac.at/1135/</a>
HSO Priorisation No. 34	published		2018	<a href="http://eprints.hta.lbg.ac.at/1149/">http://eprints.hta.lbg.ac.at/1149/</a>
HSO Priorisation No. 35	published		2018	<a href="http://eprints.hta.lbg.ac.at/1156/">http://eprints.hta.lbg.ac.at/1156/</a>
HSO Priorisation No. 36	published		2018	<a href="http://eprints.hta.lbg.ac.at/1156/">http://eprints.hta.lbg.ac.at/1156/</a>
HSO Priorisation No. 37	published		2018	<a href="http://eprints.hta.lbg.ac.at/1179/">http://eprints.hta.lbg.ac.at/1179/</a>
HSO Priorisation No. 38	published		2019	<a href="http://eprints.hta.lbg.ac.at/1189/">http://eprints.hta.lbg.ac.at/1189/</a>
HSO Priorisation No. 39	published		2019	<a href="http://eprints.hta.lbg.ac.at/1196/">http://eprints.hta.lbg.ac.at/1196/</a>
HSO Priorisation No. 40	published		2019	<a href="http://eprints.hta.lbg.ac.at/1208/">http://eprints.hta.lbg.ac.at/1208/</a>
HSO Priorisation No. 41	published		2020	<a href="http://eprints.hta.lbg.ac.at/1220/">http://eprints.hta.lbg.ac.at/1220/</a>